<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420304700</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112498</dc:identifier><eid>1-s2.0-S0223523420304700</eid><prism:doi>10.1016/j.ejmech.2020.112498</prism:doi><pii>S0223-5234(20)30470-0</pii><dc:title>Recent researches for dual Aurora target inhibitors in antitumor field </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>203</prism:volume><prism:startingPage>112498</prism:startingpage><prism:pageRange>112498</prism:pagerange><articleNumber>112498</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-10-01</prism:coverdate><prism:coverDisplayDate>1 October 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Liu, Maoyu</dc:creator><dc:creator>Ju, Xueming</dc:creator><dc:creator>Zou, Jing</dc:creator><dc:creator>Shi, Jianyou</dc:creator><dc:creator>Jia, Guiqing</dc:creator><dc:description>
                  Non-infectious and chronic diseases such as malignant tumors are now one of the main causes of human death. Its occurrence is a multi-factor, multi-step complex process with biological characteristics such as cell differentiation, abnormal proliferation, uncontrolled growth, and metastasis. It has been found that a variety of human malignant tumors are accompanied by over-expression and proliferation of Aurora kinase, which causes abnormalities in the mitotic process and is related to the instability of the genome that causes tumors. Therefore, the use of Aurora kinase inhibitors to target tumors is becoming a research hotspot. However, in cancer, because of the complexity of signal transduction system and the participation of different proteins and enzymes, the anticancer effect of selective single-target drugs is limited. After inhibiting one pathway, signal molecules can be conducted through other pathways, resulting in poor therapeutic effect of single-target drug treatment. Multi-target drugs can solve this problem very well. It can regulate the various links that cause disease at the same time without completely eliminating the relationship between the signal transmission systems, and it is not easy to cause drug resistance. Currently, studies have shown that Aurora dual-target inhibitors generated with the co-inhibition of Aurora and another target (such as CDK, PLK, JAK2, etc.) have better therapeutic effects on tumors. In this paper, we reviewed the studies of dual Aurora inhibitors that have been discovered in recent years.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Aurora kinase</dcterms:subject><dcterms:subject>Dual inhibitor</dcterms:subject><dcterms:subject>Anti-tumor</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420304700" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420304700" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="547" height="253" size="54455">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="333" height="245" size="36673">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="580" size="100403">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="165" size="26740">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="670" height="929" size="96593">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="548" height="272" size="54917">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="321" size="85201">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="333" height="178" size="28397">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="547" height="241" size="53163">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="8246">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="161" size="11049">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="158" size="12723">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="72" size="5136">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="118" height="164" size="4662">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="109" size="7722">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="99" size="7373">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="117" size="8603">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="7558">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1453" height="673" size="178999">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1476" height="1086" size="231248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="2569" size="731492">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="732" size="198219">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2966" height="4112" size="771748">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2429" height="1206" size="357270">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="1422" size="548265">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1476" height="790" size="173057">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2421" height="1067" size="332917">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1146415">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420304700-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85088017628</scopus-id><scopus-eid>2-s2.0-85088017628</scopus-eid><pubmed-id>32693295</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85088017628" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200626">2020-06-26</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200626">2020-06-26</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200718">2020-07-18</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200718">2020-07-18</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-09-10T20:42:47</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420304700</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30470-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420304700</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112498</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X0016X</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210215">2021-02-15T02:42:41.357861Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20201001</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1593193468">2020-06-26T17:44:28.544506Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>203</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>203</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 203</xocs:vol-iss-suppl-text>
      <xocs:sort-order>27</xocs:sort-order>
      <xocs:first-fp>112498</xocs:first-fp>
      <xocs:article-number>112498</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112498</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20201001</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 October 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-10-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>RECENTRESEARCHESFORDUALAURORATARGETINHIBITORSINANTITUMORFIELD</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>LIU</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>M</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Aurora dual target inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/CDK1 dual inhibitor: JNJ-7706621 (<ce:bold>1</ce:bold>)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/JAK 2 dual inhibitor: AJI-214 (<ce:bold>3</ce:bold>) and AJI-100 (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora B/FLT3 dual inhibitor: Acylureidoindoin-2-one derivatives/CCT137690/CCT241736</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/Src family kinase (SFKs): SU6656 (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/MEK dual inhibitor: BI-847325 (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/VEGFR-2 dual inhibitor: 7-[1<ce:italic>H</ce:italic>-Indol-2-yl]-2,3-dihydro-isoindol-1-ones</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/ERK 2 dual inhibitor: (7-aryl-1, 5-naphthylpyridine-2-yl)urea</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora/PDK 1 dual inhibitor: SA16 (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Perspective</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>WEINBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>70</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>43221</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>VOGELSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>159</xocs:ref-first-fp>
            <xocs:ref-last-lp>170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>MANTOVANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>436</xocs:ref-first-fp>
            <xocs:ref-last-lp>444</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>VIVANCO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>489</xocs:ref-first-fp>
            <xocs:ref-last-lp>501</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>KASTAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>316</xocs:ref-first-fp>
            <xocs:ref-last-lp>323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>LENGAUER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>643</xocs:ref-first-fp>
            <xocs:ref-last-lp>649</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>JENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2065</xocs:ref-first-fp>
            <xocs:ref-last-lp>2071</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>RIEDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>637</xocs:ref-first-fp>
            <xocs:ref-last-lp>651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>HOCHEGGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>JACKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>107</xocs:ref-first-fp>
            <xocs:ref-last-lp>117</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>VADER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>60</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>CARPINELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>69</xocs:ref-first-fp>
            <xocs:ref-last-lp>80</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>WEERDT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>853</xocs:ref-first-fp>
            <xocs:ref-last-lp>864</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>OCONNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>221</xocs:ref-first-fp>
            <xocs:ref-last-lp>228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>NICHOLAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>927</xocs:ref-first-fp>
            <xocs:ref-last-lp>936</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>CHEUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>379</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>NAIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>12893</xocs:ref-first-fp>
            <xocs:ref-last-lp>12903</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>DUTERTRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>6175</xocs:ref-first-fp>
            <xocs:ref-last-lp>6183</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>TATSUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2899</xocs:ref-first-fp>
            <xocs:ref-last-lp>2905</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>WALTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>4906</xocs:ref-first-fp>
            <xocs:ref-last-lp>4916</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>KATAYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>46219</xocs:ref-first-fp>
            <xocs:ref-last-lp>46224</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CARMENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>842</xocs:ref-first-fp>
            <xocs:ref-last-lp>854</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>5818</xocs:ref-first-fp>
            <xocs:ref-last-lp>5827</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>WENDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>122</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>MOORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>671</xocs:ref-first-fp>
            <xocs:ref-last-lp>678</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>BARR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2987</xocs:ref-first-fp>
            <xocs:ref-last-lp>2996</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>POLLARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2629</xocs:ref-first-fp>
            <xocs:ref-last-lp>2651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>MANFREDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4106</xocs:ref-first-fp>
            <xocs:ref-last-lp>4111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>VADER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>833</xocs:ref-first-fp>
            <xocs:ref-last-lp>837</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>TOMONAGA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>191</xocs:ref-first-fp>
            <xocs:ref-last-lp>197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>HUGHES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5130</xocs:ref-first-fp>
            <xocs:ref-last-lp>5133</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>KANDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7266</xocs:ref-first-fp>
            <xocs:ref-last-lp>7272</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>OTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>5168</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>679</xocs:ref-first-fp>
            <xocs:ref-last-lp>688</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>LAWRENCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7392</xocs:ref-first-fp>
            <xocs:ref-last-lp>7416</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>MANFREDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4106</xocs:ref-first-fp>
            <xocs:ref-last-lp>4111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>GREEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>291</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>ARAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2417</xocs:ref-first-fp>
            <xocs:ref-last-lp>2430</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>468</xocs:ref-first-fp>
            <xocs:ref-last-lp>483</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>SANCHEZMARTINEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>STUART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>9038</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>223</xocs:ref-first-fp>
            <xocs:ref-last-lp>236</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>BELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>724</xocs:ref-first-fp>
            <xocs:ref-last-lp>728</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>JOAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>298</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3639</xocs:ref-first-fp>
            <xocs:ref-last-lp>3641</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>ENSERINK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>MARCOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>153</xocs:ref-first-fp>
            <xocs:ref-last-lp>166</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>RONGHUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4208</xocs:ref-first-fp>
            <xocs:ref-last-lp>4211</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>HIROTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>GIET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>15005</xocs:ref-first-fp>
            <xocs:ref-last-lp>15013</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>MAEKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>438</xocs:ref-first-fp>
            <xocs:ref-last-lp>449</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>NOBLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>269</xocs:ref-first-fp>
            <xocs:ref-last-lp>278</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2221</xocs:ref-first-fp>
            <xocs:ref-last-lp>2224</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>UNITEDSTATESPATENT</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>SUBSTITUTEDPYRROLINESKINASEINHIBITORS</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>KITZEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>99</xocs:ref-first-fp>
            <xocs:ref-last-lp>110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>MATSUHASHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>625</xocs:ref-first-fp>
            <xocs:ref-last-lp>639</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>DANHIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>20</xocs:ref-first-fp>
            <xocs:ref-last-lp>28</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>WILLIAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>385</xocs:ref-first-fp>
            <xocs:ref-last-lp>393</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>HAIYING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1007</xocs:ref-first-fp>
            <xocs:ref-last-lp>1013</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>HUA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2947</xocs:ref-first-fp>
            <xocs:ref-last-lp>2961</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>PAWEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>188</xocs:ref-first-fp>
            <xocs:ref-last-lp>197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>ALFONSO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-last-lp>472</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>LEVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1738</xocs:ref-first-fp>
            <xocs:ref-last-lp>1752</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>KAZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>693</xocs:ref-first-fp>
            <xocs:ref-last-lp>703</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>MASSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1717</xocs:ref-first-fp>
            <xocs:ref-last-lp>1726</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>MOORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>671</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>CHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>8</xocs:ref-first-fp>
            <xocs:ref-last-lp>16</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>KUBLIGARFIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1377</xocs:ref-first-fp>
            <xocs:ref-last-lp>1395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>WOOD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>LOWENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>6030</xocs:ref-first-fp>
            <xocs:ref-last-lp>6036</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>VASSILIOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>8721</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>JAGTAP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>268</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>TIZIANA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>540</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79"/></xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>BAVETSIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5213</xocs:ref-first-fp>
            <xocs:ref-last-lp>5228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>MOORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>MIZUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>3907</xocs:ref-first-fp>
            <xocs:ref-last-lp>3914</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>MOORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>JAMIESON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>5029</xocs:ref-first-fp>
            <xocs:ref-last-lp>5046</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>SUMMY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>337</xocs:ref-first-fp>
            <xocs:ref-last-lp>358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>FRAME</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>114</xocs:ref-first-fp>
            <xocs:ref-last-lp>130</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>THOMAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>513</xocs:ref-first-fp>
            <xocs:ref-last-lp>609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>COLLETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1978</xocs:ref-pub-year>
            <xocs:ref-first-fp>2021</xocs:ref-first-fp>
            <xocs:ref-last-lp>2024</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>ISHIZAWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>209</xocs:ref-first-fp>
            <xocs:ref-last-lp>214</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>WEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>924</xocs:ref-first-fp>
            <xocs:ref-last-lp>935</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>FREMIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>8</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>CARGNELLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>50</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>RAMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3100</xocs:ref-first-fp>
            <xocs:ref-last-lp>3112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>SINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2388</xocs:ref-first-fp>
            <xocs:ref-last-lp>2398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>PEARSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>153</xocs:ref-first-fp>
            <xocs:ref-last-lp>183</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>CAROLINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>29887</xocs:ref-first-fp>
            <xocs:ref-last-lp>29898</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>FRANCESCO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>285</xocs:ref-first-fp>
            <xocs:ref-last-lp>294</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>HOLT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>858</xocs:ref-first-fp>
            <xocs:ref-last-lp>866</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>PHADKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1354</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>LEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1008</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4934</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>SCHOFFSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>99</xocs:ref-first-fp>
            <xocs:ref-last-lp>108</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>ARJAANS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>ROSKOSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>179</xocs:ref-first-fp>
            <xocs:ref-last-lp>213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>SHIBUYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1097</xocs:ref-first-fp>
            <xocs:ref-last-lp>1105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>183</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>126711</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1448</xocs:ref-first-fp>
            <xocs:ref-last-lp>1454</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>TARAZONA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>ALISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>13</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>ROBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>YOON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>21</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>446</xocs:ref-first-fp>
            <xocs:ref-last-lp>451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>WORTZEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>209</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>JULIEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>217</xocs:ref-first-fp>
            <xocs:ref-last-lp>232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>DEFAUX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3748</xocs:ref-first-fp>
            <xocs:ref-last-lp>3752</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>GAGLIARDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>178</xocs:ref-first-fp>
            <xocs:ref-last-lp>188</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>PEIFER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1810</xocs:ref-first-fp>
            <xocs:ref-last-lp>1838</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>GAGLIARDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>415</xocs:ref-first-fp>
            <xocs:ref-last-lp>434</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-last-lp>403</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>DANIELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>100</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>HONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>983</xocs:ref-first-fp>
            <xocs:ref-last-lp>990</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>SESTITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>274</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>LIUX2020X112498</xocs:refkey3>
         <xocs:refkey4ai>LIUX2020X112498XM</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-07-18T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-07-18T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-06-01T06:40:29.430Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>SPDST</xocs:funding-agency-acronym>
            <xocs:funding-agency>Department of Science and Technology of Sichuan Province</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004829</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30470-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420304700</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420304700</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112498</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-02-15T02:42:41.357861Z</xocs:timestamp>
         <xocs:cover-date-start>2020-10-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/MAIN/application/pdf/37d616bc26e5ac4ec4d150c9fecc3772/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2374449</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>15</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420304700-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/PREVIEW/image/png/14a539e417dcf3231265e6ffa2a54bb9/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>56818</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr6/DOWNSAMPLED/image/jpeg/817376aead8888307f9bea404e8b9745/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54455</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>547</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr2/DOWNSAMPLED/image/jpeg/88d929e6764379de004f5e8cfb1d2588/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36673</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>333</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr1/DOWNSAMPLED/image/jpeg/c58c3c5811dc9dab52c38ee1822e3f98/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>100403</xocs:filesize>
               <xocs:pixel-height>580</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/fx1/DOWNSAMPLED/image/jpeg/82eaf01497cfffc8b031f046fae3f99f/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26740</xocs:filesize>
               <xocs:pixel-height>165</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr7/DOWNSAMPLED/image/jpeg/5a937dfa8fad06b4531c354f23d053e9/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>96593</xocs:filesize>
               <xocs:pixel-height>929</xocs:pixel-height>
               <xocs:pixel-width>670</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr3/DOWNSAMPLED/image/jpeg/b328009bec9fab60d57747fed711b330/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54917</xocs:filesize>
               <xocs:pixel-height>272</xocs:pixel-height>
               <xocs:pixel-width>548</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr4/DOWNSAMPLED/image/jpeg/182db8e720e4f08b3ffdd547fee1be3e/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>85201</xocs:filesize>
               <xocs:pixel-height>321</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr8/DOWNSAMPLED/image/jpeg/7127675b2525e87d71dbcc9122785534/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28397</xocs:filesize>
               <xocs:pixel-height>178</xocs:pixel-height>
               <xocs:pixel-width>333</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr5/DOWNSAMPLED/image/jpeg/b955e9b59205c0c7cb766cc53c56d50e/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53163</xocs:filesize>
               <xocs:pixel-height>241</xocs:pixel-height>
               <xocs:pixel-width>547</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr6/THUMBNAIL/image/gif/bcf961841d7a0b4db8877411fa3fa479/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8246</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr2/THUMBNAIL/image/gif/f0ce22b9bc1232d16fb1d6b2330f385e/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11049</xocs:filesize>
               <xocs:pixel-height>161</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr1/THUMBNAIL/image/gif/a7904a6ebad3432e4a2ec6e1bfb41f10/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12723</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/fx1/THUMBNAIL/image/gif/2cac5816cccf352c4aa4d023ecd713fb/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5136</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr7/THUMBNAIL/image/gif/31dcc0fe152a13883407659b31fb31cf/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4662</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>118</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr3/THUMBNAIL/image/gif/f4fffe4458a2202e1d010db361dc8890/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7722</xocs:filesize>
               <xocs:pixel-height>109</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr4/THUMBNAIL/image/gif/008d4d2509d6aed47b28ec941d24ae23/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7373</xocs:filesize>
               <xocs:pixel-height>99</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr8/THUMBNAIL/image/gif/5078629439e75d399426453c11cb051f/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8603</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr5/THUMBNAIL/image/gif/0aada28bf0b372315371544b8bfc97d9/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7558</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr6/HIGHRES/image/jpeg/9f17926afcbcc0759b85e330d8cb0bcd/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>178999</xocs:filesize>
               <xocs:pixel-height>673</xocs:pixel-height>
               <xocs:pixel-width>1453</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr2/HIGHRES/image/jpeg/a6356d67031cb21639f9f932bda00fdb/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>231248</xocs:filesize>
               <xocs:pixel-height>1086</xocs:pixel-height>
               <xocs:pixel-width>1476</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr1/HIGHRES/image/jpeg/1be6a1852c8e38c44fc43515a0b1890b/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>731492</xocs:filesize>
               <xocs:pixel-height>2569</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/fx1/HIGHRES/image/jpeg/69414315422164b8c81357fd37345a1f/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>198219</xocs:filesize>
               <xocs:pixel-height>732</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr7/HIGHRES/image/jpeg/2b36b77dd251d78e8fad7e0efffb0fbe/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>771748</xocs:filesize>
               <xocs:pixel-height>4112</xocs:pixel-height>
               <xocs:pixel-width>2966</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr3/HIGHRES/image/jpeg/fe5b21ad4f97cb8d09c5b9562cd58de9/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>357270</xocs:filesize>
               <xocs:pixel-height>1206</xocs:pixel-height>
               <xocs:pixel-width>2429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr4/HIGHRES/image/jpeg/4f0933095eb8bdb9d026fbceba12e0ae/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>548265</xocs:filesize>
               <xocs:pixel-height>1422</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr8/HIGHRES/image/jpeg/44e319891c5edab411f16de96dd4e60b/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>173057</xocs:filesize>
               <xocs:pixel-height>790</xocs:pixel-height>
               <xocs:pixel-width>1476</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420304700/gr5/HIGHRES/image/jpeg/858ee5104337d4613b471781c024e6d5/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>332917</xocs:filesize>
               <xocs:pixel-height>1067</xocs:pixel-height>
               <xocs:pixel-width>2421</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420304700-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1146415</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10M618DLBQ1/MAIN/application/pdf/ca7c26a11e0337734df9712a06bc5a81/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112498</aid>
            <ce:article-number>112498</ce:article-number>
            <ce:pii>S0223-5234(20)30470-0</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112498</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Relationship of signaling pathways covered in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420304700/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">SAR of JNJ-7706621.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420304700/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">SAR of AJI-214.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420304700/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">SAR of Acylureidoindoin-2-one derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420304700/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">SAR of CCT137690 (compound <ce:bold>7</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420304700/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">SAR of CCT241736 (compound <ce:bold>5</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420304700/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">The Chemical structures of inhibitors in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420304700/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">SAR of 7-[1H-indol-2-yl]-2, 3-dihydro-isoindol-1-ones.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523420304700/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0010" view="all">Clinical trials of dual target inhibitors used in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Drug</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Targets</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Sponsor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Identifier</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BI-847325</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora/MEK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Boehringer Ingelheim</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Neoplasms</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01324830</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SA16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora/PDK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cochlear</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hearing loss</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not Applicable</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02852330</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">University of Concepcion, Chile</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cocaine-related Disorders</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03556371</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Instituto Milenio para Investigación en Depresión y Personalidad</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Depression</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not Applicable</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03093467</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Papworth Hospital NHS Foundation Trust</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Postoperative Delirium</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not Applicable</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01599689</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Recent researches for dual Aurora target inhibitors in antitumor field</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420304700-294cb5ea9df3b5aaf05e755dad8a7719">
                  <ce:given-name>Maoyu</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420304700-99f5df21824e2cf205b58d0051d5977d">
                  <ce:given-name>Xueming</ce:given-name>
                  <ce:surname>Ju</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420304700-10165f030cd95f382ebc13e00aa5f68c">
                  <ce:given-name>Jing</ce:given-name>
                  <ce:surname>Zou</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420304700-8c103013b97afe6d52b94528ba258493">
                  <ce:given-name>Jianyou</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" author-id="S0223523420304700-541505021e4bff595e97c11f19716b4e">
                  <ce:given-name>Guiqing</ce:given-name>
                  <ce:surname>Jia</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0055" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420304700-4ff264850df69874541726a259737a2f">
                  <ce:label>a</ce:label>
                  <ce:textfn>The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicines of Ministry, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicines of Ministry</sa:organization>
                     <sa:organization>State Key Laboratory Breeding Base of Systematic Research</sa:organization>
                     <sa:organization>Development and Utilization of Chinese Medicine Resources</sa:organization>
                     <sa:organization>Pharmacy College</sa:organization>
                     <sa:organization>Chengdu University of Traditional Chinese Medicine</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>611137</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">The Ministry of Educational Key Laboratory of Standardization of Chinese Herbal Medicines of Ministry, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, P. R. China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420304700-7709785d8fcd3f82ba2b6037435ed73c">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Gastrointestinal Surgery</sa:organization>
                     <sa:organization>Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital</sa:organization>
                     <sa:organization>University of Electronic Science and Technology of China</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610072</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420304700-cd63bd2818e7398420b4bbf7a5f70395">
                  <ce:label>c</ce:label>
                  <ce:textfn>Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Personalized Drug Therapy Key Laboratory of Sichuan Province</sa:organization>
                     <sa:organization>Department of Pharmacy</sa:organization>
                     <sa:organization>Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital</sa:organization>
                     <sa:organization>School of Medicine</sa:organization>
                     <sa:organization>University of Electronic Science and Technology of China</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610072</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Chengdu of China, Chengdu, 610072, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S0223523420304700-40340c62911908c347162d5ad7ca3239">
                  <ce:label>d</ce:label>
                  <ce:textfn>Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Ultrasound</sa:organization>
                     <sa:organization>Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital</sa:organization>
                     <sa:organization>University of Electronic Science and Technology of China</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610072</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 611731, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="21" month="3" year="2020"/></ce:date-received>
            <ce:date-revised day="5" month="5" year="2020"/></ce:date-revised>
            <ce:date-accepted day="28" month="5" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Non-infectious and chronic diseases such as malignant tumors are now one of the main causes of human death. Its occurrence is a multi-factor, multi-step complex process with biological characteristics such as cell differentiation, abnormal proliferation, uncontrolled growth, and metastasis. It has been found that a variety of human malignant tumors are accompanied by over-expression and proliferation of Aurora kinase, which causes abnormalities in the mitotic process and is related to the instability of the genome that causes tumors. Therefore, the use of Aurora kinase inhibitors to target tumors is becoming a research hotspot. However, in cancer, because of the complexity of signal transduction system and the participation of different proteins and enzymes, the anticancer effect of selective single-target drugs is limited. After inhibiting one pathway, signal molecules can be conducted through other pathways, resulting in poor therapeutic effect of single-target drug treatment. Multi-target drugs can solve this problem very well. It can regulate the various links that cause disease at the same time without completely eliminating the relationship between the signal transmission systems, and it is not easy to cause drug resistance. Currently, studies have shown that Aurora dual-target inhibitors generated with the co-inhibition of Aurora and another target (such as CDK, PLK, JAK2, etc.) have better therapeutic effects on tumors. In this paper, we reviewed the studies of dual Aurora inhibitors that have been discovered in recent years.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420304700/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Aurora kinase</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Dual inhibitor</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Anti-tumor</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Malignant tumors are commonly known as cancer. They have been recorded for more than 2000 years, and their fatality rate is high, making them the second leading cause of death worldwide. According to the World Health Organization, nearly 8.8 million people died of cancer in 2015, accounting for one-sixth of all deaths in the world. About one-third of these carcinogens include unhealthy behaviors such as excess body weight, imbalanced nutritional intake, drinking, smoking and lack of exercise. The transformation of normal cell carcinoma into tumor cells is a multi-stage process from precancerous lesions to malignant tumors. A large number of cancer cell genotypes are a collection of six basic changes in cell physiology that jointly determine malignant growth: self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis [<ce:cross-ref id="crosref0060" refid="bib1">1</ce:cross-ref>]. In most cancers, many factors, including the environment, genes and viruses, play a role in the development and progress of diseases. Genetic and molecular anomalies can be observed, which directly lead to cell cycle errors [<ce:cross-ref id="crosref0065" refid="bib2">2</ce:cross-ref>]. Studies showed that the genome of tumor cells always changes in multiple locations, through subtle damage such as point mutations and changes in chromosomal complement [<ce:cross-ref id="crosref0070" refid="bib3">3</ce:cross-ref>]. Ras family members are the most common mutation-dominant oncogenes in human cancer. The activated oncogene component of the Ras-Raf signaling pathway in turn induces tumors to promote the production of inflammatory chemokines and cytokines [<ce:cross-ref id="crosref0075" refid="bib4">4</ce:cross-ref>]. The phosphatidylinositol 3 kinase (PI3K) pathway regulates various cellular processes, such as proliferation, growth, apoptosis and cytoskeletal rearrangement [<ce:cross-ref id="crosref0080" refid="bib5">5</ce:cross-ref>]. The protein kinase B (AKT) acts downstream of PI3K to regulate many biological processes, but other signalling pathways are also known to be regulated by PI3K activity and might be involved in PI3K-mediated tumorigenesis [<ce:cross-ref id="crosref0085" refid="bib5">5</ce:cross-ref>]. The available clinical evidence of PI3K-pathway deregulation in various cancers and the identification of downstream kinases that are involved in mediating the effects of PI3K (AKT, mTOR and PDK1) provide potential targets for the development of small-molecule therapies [<ce:cross-ref id="crosref0090" refid="bib5">5</ce:cross-ref>]. Cancer has the ability to quickly produce abnormal cells, which can quickly transfer to other organs and spread to every part of the body. This is a major cause of cancer death. Cancer affects the normal function and metabolism of the human body, destroys the normal tissue structure, and seriously affects the normal life of humans. Therefore, it is urgent to find new drugs to treat tumors to reduce the suffering of patients. The relationship of signaling pathways was summarized in the <ce:cross-ref id="crosref1688" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>. In this review, we summarize some of the research findings of Aurora dual inhibitors in the past decade. The chemical structures of dual inhibitors were described in the <ce:cross-ref id="crosref1897" refid="fig7">Fig. 7</ce:cross-ref>.</ce:para>
                  <ce:para id="p0035" view="all">Mitosis is a complex process that allows repeated chromosomal components to leave and obtain two genetically identical daughter cells [<ce:cross-ref id="crosref0100" refid="bib6">6</ce:cross-ref>]. Although it is the shortest stage in the cell cycle, it can coordinate the main changes in cell components. Through signal pathways, information is transmitted to prompt the cell structure to be reorganized when proteins are degraded. Any abnormality in this process may lead to genome instability. The loss of genomic stability is considered to be one of the driving forces of tumorigenesis and development [<ce:cross-ref id="crosref0105" refid="bib7">7</ce:cross-ref>]. In most cancers, instability is observed at the chromosomal level, and various chromosomal aberrations, such as abnormal ploidy, are common in cancer cells [<ce:cross-ref id="crosref0110" refid="bib8">8</ce:cross-ref>]. The spindle assembly checkpoint (SAC) is a safeguard to ensure that chromosome segregation does not take place until all telomeres and microtubules are accurately connected [<ce:cross-ref id="crosref0115" refid="bib9">9</ce:cross-ref>]. The stress response produced by cells after being damaged by invasion can activate the SAC, leading to long-term interruption of the mitotic process, which induces death [<ce:cross-ref id="crosref0120" refid="bib10">10</ce:cross-ref>]. The failure of cell cycle checkpoint rules often leads to aneuploidy and genetic instability, and eventually reaches the peak in cell death or cancer [<ce:cross-ref id="crosref0125" refid="bib10">10</ce:cross-ref>]. The emergence of polyploid, caspase-2 activation, and death cells demonstrated that the cell death is caused by the mitosis mutation, so it is considered as the most vulnerable stage of the cell cycle [<ce:cross-ref id="crosref0130" refid="bib11">11</ce:cross-ref>]. The process of cell division is conducive to tumorigenesis and development. Targeting cell division is a successful anti-tumor treatment. So far, studies have shown that taxane and vincristine can effectively treat many tumor types [<ce:cross-ref id="crosref0135" refid="bib12">12</ce:cross-ref>]. This kind of anti-mitotic compounds target spindle and target tubulin assembly, interrupting the mitosis process. Anti-mitotic therapies that target tubulin are effective and widely used in treating cancer, but they have limitations related to the role of tubulin in the cytoskeleton of normal cells [<ce:cross-ref id="crosref0140" refid="bib13">13</ce:cross-ref>]. Tubulin can play a role in cell cycle-independent functions, such as vesicle trafficking and cell signaling, which may cause toxicity to non-dividing cells [<ce:cross-ref id="crosref0145" refid="bib13">13</ce:cross-ref>]. Recent studies have found another way to interfere with mitosis. Compounds that target regulatory proteins in the course of mitosis have the advantage of not interfering with the normal function of interphase cells compared to general microtubular kinetic compounds [<ce:cross-ref id="crosref0150" refid="bib14">14</ce:cross-ref>], and have fewer side effects and targets. Targeting non-structural components of mitosis, that is, proteins that regulate mitotic steps in the cell cycle, targeting mitosis-specific proteins may have the added advantage of not interfering with non-dividing cells [<ce:cross-ref id="crosref0155" refid="bib13">13</ce:cross-ref>]. In this context, the discovery and validation of biomarkers based on mechanisms that can be used as indicators of pharmacological responses to normal biological processes, pathogenic processes or therapeutic interventions will contribute to the effective development of new cancer drugs [<ce:cross-ref id="crosref0160" refid="bib15">15</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Subsequently, the development of anticancer drugs targeting mitotic regulatory molecules was studied. The process and execution of mitosis are subject to post-translational regulation by a variety of protein kinases, such as Polo-like kinases (PLKs) [<ce:cross-ref id="crosref0165" refid="bib16">16</ce:cross-ref>], Cyclin-dependent kinases (CDKs) [<ce:cross-ref id="crosref0170" refid="bib17">17</ce:cross-ref>], Nima kinases [<ce:cross-ref id="crosref0175" refid="bib18">18</ce:cross-ref>], Aurora kinases [<ce:cross-ref id="crosref0180" refid="bib19">19</ce:cross-ref>], etc. Aurora kinase plays an important role in spindle assembly, centrosome maturation, chromosome segregation and cytokinesis during mitosis. Some studies have shown that Aurora kinases, especially Aurora A and B, are overexpressed in various tumors and are highly related to the abnormal growth of cancer cells [<ce:cross-ref id="crosref0185" refid="bib20">20</ce:cross-ref>], and have been proven to be promising anticancer targets. Aurora kinases, including Aurora A, B, and C, are a family of Serine/Threonine kinases that have a highly conserved C-terminal kinase domain, participate in the mitotic phase of cells, and play a key role in G2 and M phases [<ce:cross-ref id="crosref0190" refid="bib21">21</ce:cross-ref>].</ce:para>
                  <ce:para id="p0045" view="all">Aurora A is located at the centrosome/spindle pole and is involved in the regulation of many early mitotic events, including mitosis, which is necessary for spindle assembly [<ce:cross-ref id="crosref0195" refid="bib22">22</ce:cross-ref>]. It involves several processes required to construct a bipolar spindle, including centrosome maturation and separation, and integration of chromosomes and metaphase plates [<ce:cross-ref id="crosref0200" refid="bib23">23</ce:cross-ref>]. Aurora A protein levels and their peaks of activation and kinase activity during mitosis are due to phosphorylation and dephosphorylation events [<ce:cross-ref id="crosref0205" refid="bib24">24</ce:cross-ref>,<ce:cross-ref id="crosref0210" refid="bib25">25</ce:cross-ref>], and their kinase activity depends on phosphorylation of Threonine 288 (Thr288) in the activation loop [<ce:cross-ref id="crosref0215" refid="bib26">26</ce:cross-ref>]. Another way to directly monitor Aurora kinase activity is to track downstream molecular events or protein stability through phosphorylation [<ce:cross-ref id="crosref0220" refid="bib15">15</ce:cross-ref>], such as P53. P53 plays an important role in deciding whether to prevent cell cycle progression or induce apoptosis in response to various stimuli [<ce:cross-ref id="crosref0225" refid="bib27">27</ce:cross-ref>]. Aurora A silencing resulted in reduced P53 phosphorylation at Serine 315 (Ser315), which is related to the stability of P53 and G2/M cell cycle arrest. Another study also showed that P53 phosphorylated at Ser215 by Aurora A is the main mechanism of P53 inactivation [<ce:cross-ref id="crosref0230" refid="bib15">15</ce:cross-ref>]. Centrosomes play a key role in maintaining the stability of the genome by organizing bipolar spindles and ensuring equal separation of replicating chromosomes to daughter cells during mitosis [<ce:cross-ref id="crosref0235" refid="bib28">28</ce:cross-ref>]. Overexpression of Aurora A and P53 mutations has been observed in a variety of tumors containing polyploid cells with abnormal centrosome numbers, and they have a synergistic effect on poor prognosis [<ce:cross-ref id="crosref0240" refid="bib8">8</ce:cross-ref>]. Selective inhibition of Aurora A can inhibit Aurora A auto-phosphorylation at Thr288, inhibit P53 phosphorylation, and inhibit unipolar spindle and G2/M arrest [<ce:cross-ref id="crosref0245" refid="bib29">29</ce:cross-ref>]. Without Aurora A, cell cycle progression, mitotic spindle polar tissue, and microtubule stability are often compromised [<ce:cross-ref id="crosref0250" refid="bib30">30</ce:cross-ref>]. The main mitotic defects were observed after the depletion of Aurora A, so it can be predicted that the selective Aurora A inhibitor will have significant anti mitotic effect [<ce:cross-ref id="crosref0255" refid="bib31">31</ce:cross-ref>]. Aurora A specific antagonist showed significant antitumor activity in xenotransplantation model and has entered phase I clinical trial [<ce:cross-ref id="crosref0260" refid="bib32">32</ce:cross-ref>].</ce:para>
                  <ce:para id="p0050" view="all">Aurora B is a chromosomal passenger protein necessary for histone H3 phosphorylation, chromosome segregation, and cytokinesis [<ce:cross-ref id="crosref0265" refid="bib19">19</ce:cross-ref>]. It forms three chromosomal passenger complexes (CPCs) with three non-enzymatic subunits: endocentric, survivin, and borealin [<ce:cross-ref id="crosref0270" refid="bib33">33</ce:cross-ref>]. It is an integral part of the mitotic “SAC”, suppressing Aurora B will cause CPC function to be impaired. The phosphorylation of Aurora B on the endocentric protein induces conformational changes, which promotes the phosphorylation of Aurora B and the full activation of kinases [<ce:cross-ref id="crosref0275" refid="bib33">33</ce:cross-ref>]. The phosphorylation of survivin at Threonine 117 (Thr117) is involved in the regulation and localization [<ce:cross-ref id="crosref0280" refid="bib33">33</ce:cross-ref>]. The persistent overexpression of Aurora B can disrupt mitotic checkpoint, cause chromosomal aberrations, and cause genomic instability and aneuploidy [<ce:cross-ref id="crosref0285" refid="bib34">34</ce:cross-ref>]. Histone H3 is a direct downstream target of Aurora kinase and is involved in chromosome enrichment and Ser10 phosphorylation and is considered to be key to correcting chromosome alignment and cytokinesis [<ce:cross-ref id="crosref0290" refid="bib35">35</ce:cross-ref>]. Inhibition of Aurora B has been shown to reduce H3 phosphorylation on Ser10 [<ce:cross-ref id="crosref0295" refid="bib35">35</ce:cross-ref>]. The histone H3 phosphorylation of Aurora B at Ser10 is a marker of mitosis, so it is widely used as a marker of mitosis and a biomarker of the activity of Aurora B in vitro and in vivo [<ce:cross-ref id="crosref0300" refid="bib15">15</ce:cross-ref>]. Some studies have shown that the phosphorylation of histone H3 on Ser10 may be necessary to induce the transformation of tumor cells [<ce:cross-ref id="crosref0305" refid="bib27">27</ce:cross-ref>], which suggests that inhibition of this phosphorylation may be directly involved in the antitumor activity observed with Aurora kinase inhibitors. We found that Aurora B activity enhanced Ras-mediated cellular transformation, and RNA interference by short hairpin RNA inhibited the transformation of Ras and its upstream oncogene Src, but not the downstream oncogene Raf [<ce:cross-ref id="crosref0310" refid="bib36">36</ce:cross-ref>]. In addition, the centromere protein in the passenger protein associated with Aurora B has a similar ability to enhance the carcinogenic Ras activity. The results showed that the increased activity of Aurora B promoted the transformation of Ras by enhancing the signal of oncogene and transforming cells with stable chromosome number into aneuploid cells [<ce:cross-ref id="crosref0315" refid="bib36">36</ce:cross-ref>]. Although Aurora B is strongly associated with cancer and plays a key role in regulating many mitotic processes, it does not transform in vitro and is generally not tumorigenic in vivo [<ce:cross-ref id="crosref0320" refid="bib36">36</ce:cross-ref>]. An important exception is that when Aurora B is overexpressed in a mutant P53 expressing cell line, tumorigenesis increases [<ce:cross-ref id="crosref0325" refid="bib37">37</ce:cross-ref>]. Although Aurora B is not a formal oncogene in itself, it can cooperate with other oncogenic mutations to promote tumor progression [<ce:cross-ref id="crosref0330" refid="bib31">31</ce:cross-ref>]. Aurora C expression is mainly restricted to the testis, and it appears to be involved in the division of meiotic cells [<ce:cross-ref id="crosref0335" refid="bib38">38</ce:cross-ref>].</ce:para>
                  <ce:para id="p0055" view="all">The Aurora kinase inhibitors can be subdivided in to three general classes: those that have selectivity for Aurora A over B, those with selectivity for Aurora B over A, and those that are potent inhibitors of both Aurora A and B [<ce:cross-ref id="crosref0340" refid="bib31">31</ce:cross-ref>]. Several Aurora kinase inhibitors including the selective Aurora A inhibitors MK-5108 and Alisertib, the selective Aurora B inhibitor Barasertib (AZD1152), and the pan-Aurora inhibitors AT9283 and Danusertib are undergoing clinical trials [<ce:cross-ref id="crosref0345" refid="bib39">39</ce:cross-ref>]. MLN8054 caused significant single-drug tumor growth inhibition in a mouse xenograft tumor model. But at the early time point when MLN8054 exposure was highest, Aurora B was transiently inhibited. This inhibition may be a contributing factor to the compound’s antitumor activity [<ce:cross-ref id="crosref0350" refid="bib40">40</ce:cross-ref>]. The small molecule inhibitors of the Aurora A and B, such as VX-680, also known as MK-0457, interfere with the function of the mitosis central body, destroy the assembly checkpoint of the mitotic spindle, and lead to the polyploidization and apoptosis of the proliferating cells [<ce:cross-ref id="crosref0355" refid="bib9">9</ce:cross-ref>]. Studies have shown that although VX-680 has shown great potential as an anticancer drug before clinical, it has failed in clinical trials due to cardiovascular side effects [<ce:cross-ref id="crosref0360" refid="bib41">41</ce:cross-ref>]. ZM47439 (dual Aurora A and B Inhibitors) is able to cause inhibition of histone H3 phosphorylation (Ser10) and endogenous replication during cell division, which leads to polyploidy and may lead to resistance [<ce:cross-ref id="crosref0365" refid="bib31">31</ce:cross-ref>]. The resistance of ZM447439 is caused by some mutations in Aurora B protein. The expression of these mutated Aurora B proteins in cells exceeds the effect of ZM447439 on histone H3 phosphorylation, cell cycle profile, and spindle checkpoints. ZM447439 and VX680 inhibitory effect on Aurora A is not complete, so the effect of inhibiting Aurora A is not good. Inhibition of Aurora kinase primarily leads to cell cycle arrest in the G2/M phase, but does not necessarily induce cell death. It may produce better results when combined with other drugs [<ce:cross-ref id="crosref0370" refid="bib31">31</ce:cross-ref>]. Cancer therapy believes that single drug targeting multiple pathways simultaneously is more effective than single pathway targeting in terms of efficacy, tolerance and economics [<ce:cross-ref id="crosref0375" refid="bib42">42</ce:cross-ref>]. Multi-target anti-tumor drugs have better efficacy than existing single-target anti-tumor drugs, which can reduce drug resistance and toxic side effects [<ce:cross-ref id="crosref0380" refid="bib43">43</ce:cross-ref>]. However, in clinical applications, it is necessary to consider the synergistic, additive or antagonistic effects of drugs [<ce:cross-ref id="crosref0385" refid="bib44">44</ce:cross-ref>]. At this time, it is particularly important to properly control the treatment of multi-target drugs [<ce:cross-ref id="crosref0390" refid="bib44">44</ce:cross-ref>]. We summarize some research results of Aurora dual target inhibitors in the treatment of cancer in recent years.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Aurora dual target inhibitors</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Aurora/CDK1 dual inhibitor: JNJ-7706621 (<ce:bold>1</ce:bold>)</ce:section-title>
                     <ce:para id="p0060" view="all">Cyclin-dependent kinases (CDKs) belong to the Serine/Threonine kinase family. They were identified as gene products involved in cell cycle regulation in the 1970s and 1980s. They can respond to extracellular and intracellular proliferation signals and control the occurrence of cell cycle checkpoint and transcription. CDKs require corresponding cyclins for stabilization, activation, and downstream phosphorylation [<ce:cross-ref id="crosref0395" refid="bib45">45</ce:cross-ref>]. The binding of catalytic kinase subunits (such as CDK1, CDK2, CDK4, or CDK6) to regulatory cell cycle subunits (such as Cyclin A, B, D1, D2, D3, or E) leads to the assembly of kinase complexes with different functions [<ce:cross-ref id="crosref0400" refid="bib46">46</ce:cross-ref>]. Under the stimulation of mitotic signals, the complex formed by the combination of D type cyclin and CDK can catalyze a series of reactions to promote the gene transcription of products required for G1/S conversion and S phase progression [<ce:cross-ref id="crosref0405" refid="bib47">47</ce:cross-ref>]. This step is a key step in controlling mitosis. The CDK2/Cyclin E, CDK4/Cyclin D and CDK6/Cyclin D complexes mainly regulate the progression from G1 to S [<ce:cross-ref id="crosref0410" refid="bib48">48</ce:cross-ref>]. CDK1/Cyclin B1 complex is necessary for the transition from G2 phase to M phase [<ce:cross-ref id="crosref0415" refid="bib49">49</ce:cross-ref>]. The key regulator of these cell cycle transitions is CDK1, which is the primary activity required for all eukaryotic cells to enter mitosis [<ce:cross-ref id="crosref0420" refid="bib50">50</ce:cross-ref>]. CDK1 interacts with 9 different cyclins throughout the cell cycle, plays an important role in limiting DNA replication, repair and isolation to specific stages of the cell cycle, and can ensure the irreversibility of each stage of the cell cycle [<ce:cross-ref id="crosref0425" refid="bib51">51</ce:cross-ref>]. Studies have shown that abnormal CDK activity is the basis of tumor cell proliferation, and its substrates and regulatory proteins are targets for genetic alterations or overexpression [<ce:cross-ref id="crosref0430" refid="bib52">52</ce:cross-ref>]. CDK1 inhibitors have the ability to inhibit tumor growth or control unregulated cell proliferation, and are expected to be used in cancer treatment [<ce:cross-ref id="crosref0435" refid="bib53">53</ce:cross-ref>]. Aurora A is required for the activation of CDK1/Cyclin B in mitosis, and is a necessary condition for CDK1/Cyclin B to be recruited to the centrosome and Aurora B [<ce:cross-ref id="crosref0440" refid="bib54">54</ce:cross-ref>]. Aurora A can phosphorylate CDC25B, which is a direct regulator of CDK1/Cyclin B1 complex. Activation of the complex is a necessary condition for mitotic entry and may provide a basis for Aurora A’s role in regulating mitotic entry [<ce:cross-ref id="crosref0445" refid="bib30">30</ce:cross-ref>]. Aurora A and CDK1/Cyclin B1 phosphorylate tubulin and regulate chromosome segregation [<ce:cross-ref id="crosref0450" refid="bib55">55</ce:cross-ref>,<ce:cross-ref id="crosref0455" refid="bib56">56</ce:cross-ref>]. Therefore, both CDK and Aurora inhibitors can block the proliferation of cancer cells by regulating the abnormal mitosis of cells, which is suitable for many tumor types [<ce:cross-ref id="crosref0460" refid="bib57">57</ce:cross-ref>]. JNJ-7706621 (<ce:cross-ref id="crosref1666" refid="fig2">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>) is a 1,2,4-triazol-3,5-diamine derivative (4-[5-amino-1-(2,6-difluorobenzoyl)-1<ce:italic>H</ce:italic>-[<ce:cross-ref id="crosref0465" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0470" refid="bib2">2</ce:cross-ref>,<ce:cross-ref id="crosref0475" refid="bib4">4</ce:cross-ref>]triazol-3-amino]benzenesulfonamide) that can inhibit CDK activity [<ce:cross-ref id="crosref0480" refid="bib53">53</ce:cross-ref>]. It is a dual target inhibitor, which has the strongest effect on CDK1 and CDK2 (IC<ce:inf loc="post">50</ce:inf> is 6 and 2 nM), and also has activity on CDK3, CDK4 and CDK6, and it can inhibit Aurora A and Aurora B (IC<ce:inf loc="post">50</ce:inf> = 11 and 15 nM) at the same time [<ce:cross-ref id="crosref0485" refid="bib46">46</ce:cross-ref>]. In a project to develop CDK inhibitors as anticancer drugs, 2,6-diamino-3-cyclopyridin [<ce:cross-ref id="crosref0490" refid="bib58">58</ce:cross-ref>] and acyltriazole-3,5-diamine derivatives [<ce:cross-ref id="crosref0495" refid="bib59">59</ce:cross-ref>] were found to be CDK inhibitors and anti-proliferative agents. For example, pyridine derivative (<ce:bold>2</ce:bold>) was found to be a selective inhibitor of CDK1 and CDK2, with moderate kinases and cellular anti-proliferative capacity. A series of acyl-substituted [<ce:cross-ref id="crosref0500" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0505" refid="bib2">2</ce:cross-ref>,<ce:cross-ref id="crosref0510" refid="bib4">4</ce:cross-ref>]triazole-3,5-diamine analogs were thus found. Testing the inhibitory activity of acyl-substituted diaminotriazole and its analogs on CDK1/Cyclin B kinase, it was found that 2,6-difluoro substitution on benzoyl is important for CDK1 activity because it increased CDK1 titer seven times more than the unsubstituted benzoyl compound [<ce:cross-ref id="crosref0515" refid="bib53">53</ce:cross-ref>]. The carbonyl group of the acyl group appeared to be critical to CDK1 activity because replacing the carbonyl linker with a methylene or sulfonyl group greatly reduced the titer of CDK1. In previous SAR studies of –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf>, it was also observed that inhibition of CDK1 and CDK2 by unsubstituted –NH<ce:inf loc="post">2</ce:inf> is critical. Any modification of the –NH<ce:inf loc="post">2</ce:inf> group was detrimental to kinase activity and cell activity [<ce:cross-ref id="crosref0520" refid="bib53">53</ce:cross-ref>]. The inhibitory activity of 2,6-difluorosubstituents on benzoyl, namely JNJ-7706621, on CDK1/Cyclin B was measured at different ATP concentrations. It was found that as the ATP content increased, the IC<ce:inf loc="post">50</ce:inf> value that inhibited CDK1 kinase activity increased proportionally. These data suggested that JNJ-7706621 may be an ATP competitive inhibitor of CDK1 [<ce:cross-ref id="crosref0525" refid="bib53">53</ce:cross-ref>]. JNJ-7706621 showed anti-proliferative activity to various human tumor cells (IC<ce:inf loc="post">50</ce:inf> of HeLa, HCT116 and A375 were 284, 254 and 447 nM, respectively) [<ce:cross-ref id="crosref0530" refid="bib50">50</ce:cross-ref>]. JNJ-7706621 (100 and 125 mg/kg) was efficacious in a human tumor xenograft model under intermittent dosing regimens [<ce:cross-ref id="crosref0535" refid="bib46">46</ce:cross-ref>]. In the study of A375 tumor xenotransplantation model, JNJ-7706621 showed 95% tumor growth inhibition [<ce:cross-ref id="crosref0540" refid="bib60">60</ce:cross-ref>]. The inhibitor blocked Ewing’s sarcoma cell line TC135 cells at the G2 phase at low concentrations, and blocked the G1 and G2 phases at high concentrations [<ce:cross-ref id="crosref0545" refid="bib61">61</ce:cross-ref>]. Aurora kinase activity requires phosphorylation of Aurora A at Thr288 and Aurora B at Thr232. CDK1 activity is positively regulated by Thr161 phosphorylation and interaction with Cyclin B1 [<ce:cross-ref id="crosref0550" refid="bib61">61</ce:cross-ref>]. Additional effects of inhibition of Aurora kinase include inhibition of histone H3 phosphorylation and endogenous replication [<ce:cross-ref id="crosref0555" refid="bib60">60</ce:cross-ref>]. CDK inhibition occurs upstream of Aurora mediated function and prevents internal replication events [<ce:cross-ref id="crosref0560" refid="bib46">46</ce:cross-ref>]. Immunoblot observations showed that JNJ-7706621 strongly and rapidly inhibited Aurora kinase within the first half hour of exposure, but only gradually reduced the phosphorylation of CDK1 (Thr161) [<ce:cross-ref id="crosref0565" refid="bib61">61</ce:cross-ref>]. JNJ-7706621 might quickly turn off the spindle checkpoint signal by inhibiting Aurora B and CDK1, causing cells to enter the late stage without chromosome alignment [<ce:cross-ref id="crosref0570" refid="bib61">61</ce:cross-ref>]. JNJ-7706621 prevented the formation of mesosomes, which affected Aurora B and downstream proteins at that site, which led to the failure of cytokinesis [<ce:cross-ref id="crosref0575" refid="bib61">61</ce:cross-ref>]. CDK1 can phosphorylate many proteins, including histone H1, DNA polymerase a, RNA polymerase II, retinoblastoma, P53, nucleolin, cAbl and laminin A. In many human cancers and cell lines, CDK and its substrates and regulatory proteins are targets for gene changes or overexpression. After treatment with JNJ-7706621, human tumor cells showed inhibition of CDK1 kinase activity, changed in CDK1 phosphorylation status, and interferenced with downstream substrates such as retinoblastoma [<ce:cross-ref id="crosref0580" refid="bib46">46</ce:cross-ref>]. The anti-proliferative effect of JNJ-7706621 may be due to the inhibition of a unique kinase subpopulation that can regulate cell growth and division, and the study found that regardless of the status of P53, retinoblastoma or the expression level of P-glycoprotein, JNJ-7706621 showed anti-proliferative activity to all the evaluated cancer cells, but less inhibitory activity to normal cells [<ce:cross-ref id="crosref0585" refid="bib46">46</ce:cross-ref>].</ce:para>
                     <ce:para id="p0065" view="all">At present, most antimitotic anti-cancer drugs have adverse side effects on cells, and CDK inhibitors have the potential to prevent cell growth with fewer side effects and to avoid the problem of multi-drug resistance [<ce:cross-ref id="crosref0590" refid="bib62">62</ce:cross-ref>]. JNJ-7706621 can inhibit cell growth, activate apoptosis and induce cytotoxicity of human cancer cells. The activity is the result of inhibiting several CDK and Aurora kinases [<ce:cross-ref id="crosref0595" refid="bib46">46</ce:cross-ref>]. In preclinical models, the effects of cell cycle progression, regulation of CDK and Aurora pathways, and induction of apoptosis indicate that JNJ-7706621 is a promising antitumor drug [<ce:cross-ref id="crosref0600" refid="bib46">46</ce:cross-ref>]. These findings support further clinical studies to determine the therapeutic potential of the compound.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Aurora/JAK 2 dual inhibitor: AJI-214 (<ce:bold>3</ce:bold>) and AJI-100 (<ce:bold>4</ce:bold>)</ce:section-title>
                     <ce:para id="p0070" view="all">JAK1, JAK2, JAK3 and Tyk2, members of the Janus kinase (JAK) family, are cytoplasmic protein tyrosine kinases, which are necessary for receptors (such as cytokine interleukin-6 (IL-6) receptor) that lack the activity of intrinsic kinase to signal [<ce:cross-ref id="crosref0605" refid="bib63">63</ce:cross-ref>]. The constituent activity of JAK protein caused by the mutation and translocation of JAK gene is related to a variety of hematopoietic malignant tumors [<ce:cross-ref id="crosref0610" refid="bib63">63</ce:cross-ref>]. JAK2 is a key mediator of cytokine receptor signaling and participates in the hematopoietic process [<ce:cross-ref id="crosref0615" refid="bib64">64</ce:cross-ref>]. Signal Transduction and Activator of Transcription (STAT) are the main substrates of JAK kinase family [<ce:cross-ref id="crosref0620" refid="bib65">65</ce:cross-ref>]. JAK2/STAT pathway is closely related to the survival and proliferation of many cancer types [<ce:cross-ref id="crosref0625" refid="bib65">65</ce:cross-ref>]. JAK2/STAT pathway is a signal cascade, which is involved in the regulation of cell proliferation and hematopoiesis, and is closely related to cell proliferative diseases [<ce:cross-ref id="crosref0630" refid="bib66">66</ce:cross-ref>]. In addition to the structural activation of JAK2/STAT pathway, JAK2 also exists in the nucleus of JAK2 V617F positive and negative hematopoietic cell lines, which means that JAK2 has an additional nuclear target [<ce:cross-ref id="crosref0635" refid="bib64">64</ce:cross-ref>]. In some leukemias and myeloproliferative tumors, constitutive JAK2 activation (V617F mutation) drives malignant transformation, which has prompted people to suppress JAK2 as a potential treatment strategy [<ce:cross-ref id="crosref0640" refid="bib67">67</ce:cross-ref>]. Studies have found that the combined use of Aurora A and JAK2 can induce untransformed cells to grow and invade in an anchor-independent manner more effectively than alone. It has also been found that gene deletion or drug inhibition of Aurora A and JAK2 is more effective in inhibiting anchor-dependent and independent growth and invasion and inducing apoptosis [<ce:cross-ref id="crosref0645" refid="bib65">65</ce:cross-ref>]. A multi-pronged approach using ectopic co-expression to prove the cooperation of Aurora A and JAK2 in transforming normal cells, as well as the gene silencing and drug inhibition of these kinases in human cancer cells [<ce:cross-ref id="crosref0650" refid="bib65">65</ce:cross-ref>]. Support the view that combined therapy targeting the Aurora A and JAK2 pathways may be more beneficial for some cancer patients. The dual inhibitors of these two kinases are more effective than targeting the corresponding kinases alone and can more effectively suppress malignancy conversion [<ce:cross-ref id="crosref0655" refid="bib65">65</ce:cross-ref>].</ce:para>
                     <ce:para id="p0075" view="all">According to the research, the biphenylpyrimidine substituted with tertiary carboxylic acid was identified as an effective type I inhibitor of the active site of Aurora kinase (Aurora A IC<ce:inf loc="post">50</ce:inf> = 6.1–1.0 nM) [<ce:cross-ref id="crosref0660" refid="bib39">39</ce:cross-ref>]. The detailed structure-activity relationship indicated that the polar substituent is the key to the activity [<ce:cross-ref id="crosref0665" refid="bib39">39</ce:cross-ref>]. Replacing the ortho-carboxyl group on the aniline ring (A) with halogen, adding fluorine to the 5-position of the pyrimidine ring, and replacing the carboxyl group on the para position of the other aniline ring (B) with an amide group increased their solubility and cell permeability [<ce:cross-ref id="crosref0670" refid="bib39">39</ce:cross-ref>]. AJI-214 (<ce:cross-ref id="crosref3355" refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>), an efficient inhibitor of Aurora A confirmed by internal chemical and structural biology studies, was obtained. AJI-100 is an analogue of AJI-214, and the only difference is that the halogen position is replaced by the positive hydrogen, which are currently thought to be inhibitors of Aurora A and JAK2 [<ce:cross-ref id="crosref0675" refid="bib65">65</ce:cross-ref>]. AJI-214 and AJI-100 inhibited Aurora A in vitro (IC<ce:inf loc="post">50</ce:inf> = 5.7 nM and 5.4 nM) and Aurora B (IC<ce:inf loc="post">50</ce:inf> = 15.6 nM and 14.0 nM). In addition, both inhibitors also inhibited JAK2 (IC<ce:inf loc="post">50</ce:inf> = 33.4 nM and 51 nM) potently. Through synthetic aperture radar (SAR), X-ray structure, and focused library synthesis, we found that fluorine binding to the 5-position of the pyrimidine ring and chlorine in the positive position of the benzene ring greatly improved the potency in vitro [<ce:cross-ref id="crosref0680" refid="bib39">39</ce:cross-ref>]. SAR data indicated that the position of the carboxylic acid moiety in AJI-214 is critical to activity [<ce:cross-ref id="crosref0685" refid="bib39">39</ce:cross-ref>]. The substitution of hydrogen or morpholine for the carboxylic acid of B ring in AJI-214 resulted in 13 times or 10 times loss of inhibitory activity, respectively, which indicated that carboxylic acid was the key to its activity [<ce:cross-ref id="crosref0690" refid="bib39">39</ce:cross-ref>]. When ring A was substituted by halogen (Cl, Br) in the ortho position and carboxylic acid was present in the para position of ring B, the compound will improve the efficacy by 1.5 to 3 times. When the 5-position of pyrimidine ring was replaced by fluorine, the activity of the compound in vitro was further improved and it was the most effective inhibitor (IC<ce:inf loc="post">50</ce:inf> between 0.8 and 4 nM). Replacing the carboxylic acid on the B ring with carboxamide greatly increased the activity of the compound and inhibited the phosphorylation of histone H3 and Aurora (Thr288) [<ce:cross-ref id="crosref0695" refid="bib39">39</ce:cross-ref>]. Genetic and pharmacological studies showed that these two inhibitors can block the auto-phosphorylation of Aurora A (Thr288) and the phosphorylation of Aurora B substrate histone H3 (Ser10) and JAK2 substrate STAT3 (Y705), inhibit anchor-dependent and independent cell growth and invasion, induce G2/M cell cycle accumulation and apoptosis, and inhibit the development of tumor [<ce:cross-ref id="crosref0700" refid="bib65">65</ce:cross-ref>]. But the accumulation of G2/M mediated by AJI-214 mainly depends on its ability to inhibit Aurora, not JAK2 [<ce:cross-ref id="crosref0705" refid="bib65">65</ce:cross-ref>]. Finally, AJI-100 can also make the mouse transplanted tumor subside, so it is of far-reaching significance to study Aurora/JAK2 dual inhibitors as potential antitumor drugs [<ce:cross-ref id="crosref0710" refid="bib65">65</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Aurora B/FLT3 dual inhibitor: Acylureidoindoin-2-one derivatives/CCT137690/CCT241736</ce:section-title>
                     <ce:para id="p0085" view="all">FMS like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase of platelet-derived growth factor receptor (PDGFR) subfamily, which is of great significance to the development of hematopoietic and immune systems [<ce:cross-ref id="crosref0715" refid="bib68">68</ce:cross-ref>]. PDGFR has been identified as a pathogenic factor of specific hematological malignancies in constitutive activated tyrosine kinas [<ce:cross-ref id="crosref0720" refid="bib68">68</ce:cross-ref>]. FLT3 signal transduction mediated by activated FLT3 is tightly regulated by adapter proteins [<ce:cross-ref id="crosref0725" refid="bib69">69</ce:cross-ref>] and can affect the proliferation, survival, and differentiation of hematopoietic stem cells and progenitor cells under normal conditions [<ce:cross-ref id="crosref0730" refid="bib70">70</ce:cross-ref>]. Mutations often occur in acute myeloid leukemia (AML), which results in independent activation of receptors and ligands for downstream signals [<ce:cross-ref id="crosref0735" refid="bib69">69</ce:cross-ref>], including internal tandem repeats (FLT3-ITD). Patients carrying these mutations are often found to have poor prognosis [<ce:cross-ref id="crosref0740" refid="bib71">71</ce:cross-ref>]. For AML, evidence to date suggested that inhibition of FLT3 is a key component of the efficacy of FLT3-ITD cell lines [<ce:cross-ref id="crosref0745" refid="bib33">33</ce:cross-ref>]. FLT3 mutations usually lead to abnormal activation. In the absence of ligand binding, auto-phosphorylation activates downstream signaling pathways, leading to abnormal proliferation of hematopoietic cells and lymphocytes, and various blood malignancies [<ce:cross-ref id="crosref0750" refid="bib43">43</ce:cross-ref>]. Some important findings have confirmed that FLT3 is an attractive target for small molecule receptor inhibitor-based therapy [<ce:cross-ref id="crosref0755" refid="bib72">72</ce:cross-ref>]. However, the use of FLT3 inhibitors such as Sorafenib and AC220 in the treatment of AML can rapidly cause acquired resistance [<ce:cross-ref id="crosref0760" refid="bib73">73</ce:cross-ref>]. Inhibition of Aurora A and B can lead to cell death, and studies have shown that the Aurora kinase inhibitor was effective in the treatment of AML [<ce:cross-ref id="crosref0765" refid="bib74">74</ce:cross-ref>]. Furthermore, Aurora B was functionally more significant for the survival of AML cells than Aurora A inhibitor [<ce:cross-ref id="crosref0770" refid="bib75">75</ce:cross-ref>]. Inhibition of Aurora B may overcome resistance to FLT3 inhibitors by impairing CPC function [<ce:cross-ref id="crosref0775" refid="bib33">33</ce:cross-ref>]. Therefore, targeting both Aurora and FLT3 kinases is a promising AML treatment [<ce:cross-ref id="crosref0780" refid="bib76">76</ce:cross-ref>].</ce:para>
                     <ce:para id="p0090" view="all">A series of 6-acylureido derivatives containing a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors [<ce:cross-ref id="crosref0785" refid="bib77">77</ce:cross-ref>]. (<ce:italic>Z</ce:italic>)-<ce:italic>N</ce:italic>-(2-(pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1<ce:italic>H</ce:italic>-pyrrole-3-carboxamide (<ce:bold>54</ce:bold>) (<ce:bold>5</ce:bold>) (<ce:cross-ref refid="fig4" id="crosref8888">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>) was identified as a dual Aurora B/FLT3 inhibitor (IC<ce:inf loc="post">50</ce:inf> = 0.4 nM and 0.5 nM) and was very cytotoxic (IC<ce:inf loc="post">50</ce:inf> = 2.4 nM, 0.7 nM, 48.9 nM, and 2.8 nM against MV4-11, MOLM-13, THP-1, and HL60 cells, respectively). In addition to the FLT3, the 4-methoxybenzoylureido moiety in the compound <ce:bold>54</ce:bold> also had an inhibitory activity against Aurora B [<ce:cross-ref id="crosref0790" refid="bib77">77</ce:cross-ref>]. It is generally considered that the acyl urea adopts a closed pseudo six-membered ring conformation due to intramolecular hydrogen bonding [<ce:cross-ref id="crosref0795" refid="bib77">77</ce:cross-ref>]. A structure-activity relationship study confirmed the significance of 6-acylureido and 3-pyrrolemethylene subunits attached to indole-2-one scaffolds, involving strong kinase inhibitory activity and cytotoxicity, and the best inhibitory activity for Aurora B and FLT3 [<ce:cross-ref id="crosref0800" refid="bib77">77</ce:cross-ref>]. The fluorine substituent on 4-methoxyphenyl group also showed inhibitory activity against Aurora B and FLT3, and greatly improved lipophilicity, bioavailability and solubility. The two methyl groups and <ce:italic>N</ce:italic>-(2-(pyrrolidone-1-yl)ethyl)carboxyamides in compound <ce:bold>54</ce:bold> can enhance its inhibitory activity of Aurora B (IC<ce:inf loc="post">50</ce:inf> = 1.9 nM) and FLT3 (IC<ce:inf loc="post">50</ce:inf> = 179.8 nM), and compound <ce:bold>54</ce:bold> displayed improved cytotoxicity against MV4-11 (IC<ce:inf loc="post">50</ce:inf> = 12.0 nM), MOLM-13 (IC<ce:inf loc="post">50</ce:inf> = 9.0 nM), THP-1 (IC<ce:inf loc="post">50</ce:inf> = 78.4 nM), and HL60 (IC<ce:inf loc="post">50</ce:inf> = 15.8 nM) cells [<ce:cross-ref id="crosref0805" refid="bib77">77</ce:cross-ref>]. Compound <ce:bold>54</ce:bold> significantly activated caspase3 and 8 in MOLM-13 and THP-1 cells in a concentration-dependent manner, and it can inhibit MOLM-13 cells [<ce:cross-ref id="crosref0810" refid="bib77">77</ce:cross-ref>]. The results showed that the levels of phosphorylated forms of direct downstream substrates histone H3 and signal transducer and transcriptional activator 5 (STAT5) in MOLM-13 cells were decreased in a concentration-dependent manner, specifically inducing exogenous apoptosis, which was the result of the dual inhibition of Aurora B and FLT3 [<ce:cross-ref id="crosref0815" refid="bib9">9</ce:cross-ref>,<ce:cross-ref id="crosref0820" refid="bib77">77</ce:cross-ref>]. Compound <ce:bold>54</ce:bold> mesylate can effectively inhibit the tumor growth of AML-MOLM13 cells transplanted into BALB/C nude mice and reduce its mortality [<ce:cross-ref id="crosref0825" refid="bib78">78</ce:cross-ref>]. Derivatives of the indolin-2-one scaffold are a prototypical class of protein kinase inhibitors [<ce:cross-ref id="crosref0830" refid="bib77">77</ce:cross-ref>]. Among them Sunitinib [<ce:cross-ref id="crosref0835" refid="bib79">79</ce:cross-ref>] was the first multi-kinase inhibitor in clinical use for treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors. Compared with the effect of Sunitinib on FLT3-WT AML cells, compound <ce:bold>54</ce:bold> was more effective and has better cell effects on Sunitinib resistant FLT3-ITD AML cells [<ce:cross-ref id="crosref0840" refid="bib78">78</ce:cross-ref>]. Compound <ce:bold>54</ce:bold> had good pharmacology and safety in vitro and in vivo, as well as good solubility and permeability, and had acceptable pharmacokinetic characteristics in vivo when administered intravenously [<ce:cross-ref id="crosref0845" refid="bib77">77</ce:cross-ref>]. At present, there are not many studies on compound <ce:bold>54</ce:bold>, but the development of this dual Aurora B/FLT3 inhibitor is of great significance in the treatment of AML.</ce:para>
                     <ce:para id="p0095" view="all">CCT137690 (<ce:bold>6</ce:bold>) (<ce:cross-ref id="crosref1677" refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>) is a derivative based on imidazolo[4, 5-b]pyridine skeleton, which is an effective oral bioavailable FLT3 and pan-Aurora inhibitor (IC<ce:inf loc="post">50</ce:inf> values of Aurora A, Aurora B, Aurora C and FLT3 were 15 nM, 25 nM, 19 nM and <0.5 nM, respectively) [<ce:cross-ref id="crosref0850" refid="bib80">80</ce:cross-ref>]. CCT137690 effectively inhibited the viability of FLT3-ITD positive human AML cell lines MOLM-13 and MV4-11 in vitro (IC50 values were 23 and 62 nM, respectively). The lead optimization study with compound 7 as the starting point had led to a new kind of imidazole[4,5-b]pyridyl Aurora kinase inhibitor, which had a 1-benzylpiperazinyl sequence at position 7 and showed good properties in vitro. Subsequent refinement of physicochemical properties by the addition of solubilizing groups identified 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3<ce:italic>H</ce:italic>-Imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (CCT137690) was a potent Aurora kinase [<ce:cross-ref id="crosref0855" refid="bib80">80</ce:cross-ref>]. Compound <ce:bold>7</ce:bold> inhibited Aurora A, B, and C (IC<ce:inf loc="post">50</ce:inf> = 0.042, 0.198, and 0.227 μM, respectively), and also inhibited cell proliferation in a series of cancer cell lines [<ce:cross-ref id="crosref0860" refid="bib81">81</ce:cross-ref>]. The collision detection chemistry of lead showed that substitution at the 6-position was sterically limited.however, comparing to the unsubstituted compound at position 6, compound 7 was a very effective Aurora A inhibitor [<ce:cross-ref id="crosref0865" refid="bib80">80</ce:cross-ref>]. The R2 dimethylaminophenyl moiety of compound <ce:bold>7</ce:bold> should also be substituted as the aniline derivative was related to toxicity. Therefore, the R1 substituent was explored, and Br was found to have good tolerance. The Br substituted compounds showed Aurora IC<ce:inf loc="post">50</ce:inf> and HCT116 GI<ce:inf loc="post">50</ce:inf> similar to compound <ce:bold>7</ce:bold> [<ce:cross-ref id="crosref0870" refid="bib80">80</ce:cross-ref>]. After further substitution of the 2-aryl substituent with a proton, the titer of Aurora A decreased by 10 times, indicating that the phenyl ring plays an important role in binding to the Aurora A and consequent translation to cell based anti-proliferative activity [<ce:cross-ref id="crosref0875" refid="bib80">80</ce:cross-ref>]. The introduction of 5-methylisoxazole made the compound well tolerated, and can effectively inhibit the growth of Aurora A and HCT116 cells (IC<ce:inf loc="post">50</ce:inf> = 0.017, GI<ce:inf loc="post">50</ce:inf> = 0.54 μM), and has a good effect in mouse liver microsomes (the remaining 50% after 30 min of incubation). However, this compound still had the problems of low bioavailability and low water solubility, which may limit its application. For selected examples, substituents containing basic nitrogen were found to increase solubility, and finally CCT137690 was obtained [<ce:cross-ref id="crosref0880" refid="bib80">80</ce:cross-ref>]. In cell assays using FLT3-ITD positive MOLM-13 cells, CCT137690 inhibited the auto-phosphorylation of Aurora A and Aurora B as well as the phosphorylation of histone H3. It also inhibited the auto-phosphorylation of FLT3 and its downstream targets phosphoric acid STAT5 and phosphoric acid P44/42 MAPK [<ce:cross-ref id="crosref0885" refid="bib82">82</ce:cross-ref>]. STAT5 was the direct downstream substrate of FLT3-ITD, and its strong inhibition of phosphorylation was consistent with the in vitro signal, which can be used as an alternative marker of FLT3 inhibition in vivo [<ce:cross-ref id="crosref0890" refid="bib83">83</ce:cross-ref>]. CCT137690 was used to inhibit both Aurora and FLT3 kinase in FLT3-ITD positive AML, which can induce cell apoptosis and lead to unique cell cycle spectrum, and make cells accumulate in G2/M [<ce:cross-ref id="crosref0895" refid="bib82">82</ce:cross-ref>]. In FLT3-ITD positive AML, FLT3 kinase was constitutively activated, and FLT3 inhibition by CCT137690 was dominant, while in FLT3-WT AML, Aurora kinase inhibition was dominant [<ce:cross-ref id="crosref0900" refid="bib84">84</ce:cross-ref>]. Based on in vitro activity, human tumor xenograft experiments were performed in nude mice. Compared with the selective FLT3 inhibitor MLN518, CCT137690 significantly reduced tumor growth and made MOLM-13-RES cells which is resistant to MLN518 sensitive to CCT137690, resulting in significant growth inhibition in vivo [<ce:cross-ref id="crosref0905" refid="bib84">84</ce:cross-ref>]. In the in vivo efficacy evaluation, CCT137690 inhibited the growth of SW620 colon cancer cell xenografts after oral administration, and no toxicity determined by weight loss was observed. However, CCT137690 had a small margin of safety for hERG, which may limit its preclinical development [<ce:cross-ref id="crosref0910" refid="bib80">80</ce:cross-ref>]. In FLT3-ITD positive AML model, the effective preclinical activity of CCT137690 supported more and more evidences, which proved that dual pan Aurora and FLT3 kinases inhibitors may be beneficial to high-risk groups of FLT3-ITD positive AML, including patients with FLT3 inhibitor resistance [<ce:cross-ref id="crosref0915" refid="bib82">82</ce:cross-ref>].</ce:para>
                     <ce:para id="p0100" view="all">However, the preclinical development of CCT137690 was limited by a narrow safety margin against hERG (IC<ce:inf loc="post">50</ce:inf> = 3.0 μM) and low human liver microsomal stability (86% metabolized after a 30 min incubation, unpublished data) [<ce:cross-ref id="crosref0920" refid="bib76">76</ce:cross-ref>]. So we optimized the imidazo[4,5-b]pyridine Aurora kinase inhibitors and identified 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl)-3<ce:italic>H</ce:italic>-imidazo[4,5-b]pyridine (CCT241736) (<ce:bold>7</ce:bold>) (<ce:cross-ref id="crosref7866" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>), a potent dual inhibitor of FLT3 and Aurora kinases with few off-target kinase activities across the kinome (IC<ce:inf loc="post">50</ce:inf> values for FLT3, Aurora A and Aurora B were 35, 15 and 100 nM, respectively) [<ce:cross-ref id="crosref0925" refid="bib76">76</ce:cross-ref>]. We used CCT137690 and its -Cl counterpart <ce:bold>5</ce:bold> as the starting point for pharmaceutical chemistry optimization, and found that if the transfer of the <ce:italic>N</ce:italic>-methylpiperazine moiety in compound <ce:bold>5</ce:bold> to the m-position was beneficial in reducing affinity for hERG and significantly increasing the human liver microsomal stability [<ce:cross-ref id="crosref0930" refid="bib76">76</ce:cross-ref>]. Replacement of the R2 (4-methylpiperazin-1-yl) phenyl substituent with five-membered heteroaromatics led to the identification of 1,3-dimethyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl as an optimal R2 substituent. Subsequent property refinement by R3 substituent modification led to CCT241736 [<ce:cross-ref id="crosref0935" refid="bib76">76</ce:cross-ref>]. It was reported that basic nitrogen in lipophilic molecules can increase hERG inhibition through cation accumulation [<ce:cross-ref id="crosref0940" refid="bib85">85</ce:cross-ref>]. Therefore, one of the most common strategies for designing hERG safety was to reduce pKa and/or introduce space volume or shield alkaline nitrogen [<ce:cross-ref id="crosref0945" refid="bib85">85</ce:cross-ref>]. Thus, 1-methyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl analogue was introduced at the para position of the phenyl group, which improved the ability to inhibit Aurora A and tumor cells and reduced the affinity of hERG [<ce:cross-ref id="crosref0950" refid="bib76">76</ce:cross-ref>]. Later, an additional methyl group was introduced at the 3 position of the pyrazole ring, which enhanced the inhibitory effect against Aurora A and the growth inhibitory ability of SW620 cells. The data showed that 1,3-dimethyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl was an optimal R2 substituent [<ce:cross-ref id="crosref0955" refid="bib76">76</ce:cross-ref>]. The incorporation of a Br or Cl substituent at the C6 position resulted in a significant increase in enzyme inhibitory activity with 6-Br/Cl derivatives >8-fold more potent relative to their unsubstituted counterparts. In order to further improve the in vitro characteristics, a <ce:italic>p</ce:italic>-chlorophenyl substituent was introduced at R3, and the obtained compound was beneficial for inhibiting the growth of SW620 tumor cells and effectively inhibiting Aurora A and FLT3 [<ce:cross-ref id="crosref0960" refid="bib76">76</ce:cross-ref>].</ce:para>
                     <ce:para id="p0105" view="all">CCT241736 showed anti-proliferative activity in HCT116 human colon cancer (GI<ce:inf loc="post">50</ce:inf> = 0.300 μM) and human FLT3-ITD positive AML cell lines MOLM-13 (GI<ce:inf loc="post">50</ce:inf> = 0.104 μM) and MV4-11 (GI<ce:inf loc="post">50</ce:inf> = 0.291 μM). In HeLa cervical cancer cells, CCT241736 inhibited both the auto-phosphorylation of Aurora A at Thr288 and histone H3 phosphorylation at Ser10, and also inhibited Aurora A in MOLM-13 cells with concomitant inhibition of FLT3 signaling [<ce:cross-ref id="crosref0965" refid="bib76">76</ce:cross-ref>]. In vivo experiments, CCT241736 strongly inhibited the growth of FLT3-ITD positive AML human tumor xenograft tumors through biomarker regulation and plasma free drug exposure. It has been selected as a preclinical development candidate for the treatment of human malignancies and has particular relevance for the treatment of AML in adults and children with existing therapies [<ce:cross-ref id="crosref0970" refid="bib76">76</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Aurora/Src family kinase (SFKs): SU6656 (<ce:bold>8</ce:bold>)</ce:section-title>
                     <ce:para id="p0110" view="all">Src family kinases (SFKs), a subclass of membrane related non-receptor tyrosine kinases, are involved in the regulation of cell proliferation, migration, differentiation and survival [<ce:cross-ref id="crosref0975" refid="bib86">86</ce:cross-ref>]. There are nine members in the Src family, including c-Src, c-Yes, Fyn, Lyn, LK, Hck, Blk, Fgr, and Yrk [<ce:cross-ref id="crosref0980" refid="bib86">86</ce:cross-ref>]. All Src family kinases contain an amino terminal membrane localization signal, also known as Src homologous 4 or SH4 domain, a unique domain with poor conservation, a SH3 domain, a SH2 domain, a tyrosine kinase domain and a regulatory sequence [<ce:cross-ref id="crosref0985" refid="bib87">87</ce:cross-ref>]. SH1 is a catalytic domain that binds to ATP and substrate peptides and mediates phosphorylation. The C-terminal is a negative regulatory region containing tyrosine residues (human: Tyr530) or tyrosine residues (mouse: Tyr527). When C-terminal Src kinase (Csk) is phosphorylated, it can interact with the SH2 domain. The activation of Src kinase usually occurs in the cell membrane. Through the Csk, the intramolecular SH2 domain is combined with the C-terminal Tyr530 and phosphorylated, making the molecule curled up and down, covering the active center of the enzyme, and suppressing the activity of Src kinase. Tyr419 dephosphorylation can promote Src kinase activation. The prototype member of Src family protein tyrosine kinase was first identified as the oncogenic retrovirus (RSV) transforming protein (v-Src) [<ce:cross-ref id="crosref0990" refid="bib88">88</ce:cross-ref>]. Later, in the process of studying this protein, we found that it has the activity of tyrosine protein kinase and can induce malignant transformation of many cell types [<ce:cross-ref id="crosref0995" refid="bib89">89</ce:cross-ref>], which led to the study of the role of the virus and cell form of Src family kinase in the regulation of cell proliferation. The constitutively activated variants of Src family kinases, including viral oncoproteins v-Src and v-Yes, and their cellular counterparts c-Src and c-Yes are over expressed and/or over activated in a variety of human epithelial tumors, may be involved in human carcinogenesis [<ce:cross-ref id="crosref1000" refid="bib86">86</ce:cross-ref>]. SH2 and SH3 domains play a central role in the regulation of SFKs catalytic activity by interacting with amino acids in the catalytic domain and N-terminal and C-terminal of residues respectively [<ce:cross-ref id="crosref1005" refid="bib88">88</ce:cross-ref>]. Src family kinases maintain their activity through a series of intramolecular interactions, which limits the accessibility of the active sites of ATP and substrate kinase domains, and limits the binding surface of SH3 and SH2 domains, thus further limiting the potential of these proteins to participate in cell signal transduction [<ce:cross-ref id="crosref1010" refid="bib86">86</ce:cross-ref>]. In cells, endogenous Src change from inactive to active through various mechanisms, and at the same time relieves the restriction on the homology (SH) domain of Src interacting with kinase and protein. Src and its downstream effectors affect cell adhesion and cytoskeleton regulation, thus controlling cell migration [<ce:cross-ref id="crosref1015" refid="bib87">87</ce:cross-ref>]. Src family kinases are involved in the development of tumors in many ways, including proliferation, destruction of cell/cell contact, migration, invasiveness, anti-apoptosis and angiogenesis, where abnormal expression or activity of Src may be the key to the disease [<ce:cross-ref id="crosref1020" refid="bib86">86</ce:cross-ref>]. Although Src is closely related to malignant tumors, Src itself is only weakly carcinogenic. Therefore, it has been suggested that Src works in concert with signaling proteins including receptor tyrosine kinases, cytokine receptors, steroid receptors, integrins and G-protein coupled receptors [<ce:cross-ref id="crosref1025" refid="bib90">90</ce:cross-ref>]. The contribution of Src to tumor development may depend on the microenvironment. In fact, the effectiveness of Src inhibition is altered by environmental factors [<ce:cross-ref id="crosref1030" refid="bib91">91</ce:cross-ref>]. Src and Aurora kinases are the central “centrals” of the oncogenic signaling network [<ce:cross-ref id="crosref1035" refid="bib42">42</ce:cross-ref>]. In multiple human malignancies, the dual inhibition of these kinases by a single drug may have broad clinical benefits in cancer treatment [<ce:cross-ref id="crosref1040" refid="bib42">42</ce:cross-ref>].</ce:para>
                     <ce:para id="p0115" view="all">SU6656 (2-oxo-3-(4,5,6,7-tetrahydro-1<ce:italic>H</ce:italic>-indol-2-ylmethylene)-2,3-dihydro-1<ce:italic>H</ce:italic>-indole-5-sulfonic acid dimethylamide) was initially found to be a specific Src inhibitor reagent [<ce:cross-ref id="crosref1045" refid="bib42">42</ce:cross-ref>]. After further study, it was found that SU6656 has a new synergistic inhibitory effect on Src (IC<ce:inf loc="post">50</ce:inf> = 280 nM) and Aurora. It can significantly inhibit tumor development, tumor progression and angiogenesis of synovial sarcoma in vivo, and specifically induce G2/M phase arrest, cytokinesis failure and apoptosis [<ce:cross-ref id="crosref1050" refid="bib42">42</ce:cross-ref>]. However, SU6656 has an inhibitory effect on Aurora B/C and has no inhibitory effect on Aurora A, similar to the Aurora B specific inhibitor AZD1152 in current clinical trials [<ce:cross-ref id="crosref1055" refid="bib42">42</ce:cross-ref>]. Studies using SU6656 derivatives demonstrated that SFK inhibition represses the activation of PI3K/AKT signalling, the transcription factor STAT3 and focal adhesion kinase (FAK), in addition to tumour cell proliferation [<ce:cross-ref id="crosref1060" refid="bib42">42</ce:cross-ref>]. Structural analysis of the Src and Aurora kinases revealed broad similarities in their catalytic domains and revealed a potential binding pattern of SU6656 to the ATP-binding cleft of Aurora B via four hydrogen bonds [<ce:cross-ref id="crosref1065" refid="bib42">42</ce:cross-ref>]. The study also evaluated the effect of SU6656 on the survival and proliferation of synovial sarcoma cells. The tumor volume and weight were significantly reduced to 16% and 13%, respectively. Src induced phosphorylation was mainly attenuated by SU6656, which confirming that SU6656 is a reliable high-fidelity SFK inhibitor [<ce:cross-ref id="crosref1070" refid="bib42">42</ce:cross-ref>]. SU6656 eliminated histone H3 phosphorylation in Fuji cells and induced P53 accumulation at concentrations higher than 2 μM. SU6656 treatment of Fuji cells attenuates phosphorylation levels of Aurora kinase and histone H3 in a dose-dependent manner [<ce:cross-ref id="crosref1075" refid="bib42">42</ce:cross-ref>]. SU6656 can also inhibit the development and progress of synovial sarcoma in preclinical animal model by dual inhibition of Src and Aurora kinases [<ce:cross-ref id="crosref1080" refid="bib42">42</ce:cross-ref>]. The decrease of tumor invasion and angiogenesis is caused by the inhibition of Src alone. Therefore, single drug such as SU6656 can inhibit both Src and Aurora kinases simultaneously, which is an effective and valuable molecular therapy strategy targeting in vivo synovial sarcoma [<ce:cross-ref id="crosref1085" refid="bib42">42</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">Aurora/MEK dual inhibitor: BI-847325 (<ce:bold>9</ce:bold>)</ce:section-title>
                     <ce:para id="p0120" view="all">Ras-Raf-MEK-ERK1/2 pathway is the most frequently maladjusted signal pathway in human cancer, which is the main regulator of cell proliferation and survival, and plays a key role in regulating various cell functions in normal and healthy tissues [<ce:cross-ref id="crosref1090" refid="bib92">92</ce:cross-ref>]. In human malignant tumors, the abnormal activation of receptor tyrosine kinase or the increase of Ras or Raf gene mutation are often observed. Therefore, these signal transduction elements are potential therapeutic targets for various cancer drug interventions [<ce:cross-ref id="crosref1095" refid="bib92">92</ce:cross-ref>]. Mitogen-activated protein kinases (MAPKs) are Ser/Thr kinases that convert extracellular stimuli into a variety of cellular responses. MAPKs are one of the oldest signal transduction pathways and are widely used in the entire evolution process in many physiological processes. All eukaryotic cells have multiple MAPK pathways, which coordinately regulate gene expression, mitosis, metabolism, exercise, survival, apoptosis, and differentiation [<ce:cross-ref id="crosref1100" refid="bib93">93</ce:cross-ref>]. The basic signaling of ERK1/2 steps follow a three-stage enzymatic cascade of MAPKs, namely upstream activated protein → MAPKK kinase (MAPKKK) → MAPK kinase (MAPKK) → MAPK. In the transmission pathway, Ras acts as an upstream activating protein, Raf acts as MAPKKK, MAPK/ERK kinase (MEK) acts as MAPKK, ERK is MAPK, and Ras-Raf-MEK-ERK pathway [<ce:cross-ref id="crosref1105" refid="bib94">94</ce:cross-ref>]. From the technical perspective of cancer treatment, inhibition of downstream sensor MEK kinase seems to be a more feasible approach [<ce:cross-ref id="crosref1110" refid="bib95">95</ce:cross-ref>]. MEK1 and MEK2 are a bispecific enzyme belonging to the MAPK kinase family that can phosphorylate the hydroxyl side chains of Ser/Thr and tyrosine residues in MAPK substrates, but each MEK phosphorylates only one or several MAPK [<ce:cross-ref id="crosref1115" refid="bib96">96</ce:cross-ref>]. Some preclinical studies have shown that simultaneous inhibition of MEK and Aurora kinase may be more effective than monotherapy. For example, Aurora B is regulated by mitogen activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) signal pathway, and its expression in melanoma and cancer cell lines is up-regulated by MEK signal, which is a valuable potential target in melanoma cells [<ce:cross-ref id="crosref1120" refid="bib97">97</ce:cross-ref>,<ce:cross-ref id="crosref1125" refid="bib98">98</ce:cross-ref>]. The combination of Aurora and MEK inhibitors is a reasonable way to block the effective pathway by reducing the expression of Aurora B and inhibiting the catalytic activity of residual enzyme. There was also evidence that melanoma cells with acquired BRAF inhibitor resistance were more dependent on Aurora B [<ce:cross-ref id="crosref1130" refid="bib97">97</ce:cross-ref>]. Compared with single drug therapy, the combination of Aurora B inhibitor (Barasertib) and MEK inhibitor (Selumetini) can improve the therapeutic effect in the mice xenotransplantation model of KRAS mutant human non-small cell lung cancer [<ce:cross-ref id="crosref1135" refid="bib99">99</ce:cross-ref>].</ce:para>
                     <ce:para id="p0125" view="all">BI-847325 is a 6-alkyl indole ketone derivative. It was initially found in the lead optimization program to find an efficient Aurora B inhibitor. It is a new type of ATP competitive oral Aurora and MEK inhibitor (IC<ce:inf loc="post">50</ce:inf> values of Aurora A, Aurora B, Aurora C, MEK1 and MEK2 were 25 nM, 3 nM, 15 nM, 25 nM, 4 nM, respectively), which can reduce expression of phospho-ERK and phospho-histone 3 [<ce:cross-ref id="crosref1140" refid="bib100">100</ce:cross-ref>]. BI-847325 treatment was also associated with up-regulation of BIM and down-regulation of Mcl-1 expression [<ce:cross-ref id="crosref1145" refid="bib100">100</ce:cross-ref>]. BIM is a BH3-specific protein that induces cell death by combating the pro-survival effects of Bcl-2, Bcl-xl, Bcl-w and Mcl-1 [<ce:cross-ref id="crosref1150" refid="bib101">101</ce:cross-ref>]. Mcl-1 is a key regulator of the sensitivity of melanoma cells to MEK inhibition [<ce:cross-ref id="crosref1155" refid="bib102">102</ce:cross-ref>]. Aurora B of Xenopus laevis is closely related to human homologous genes and is considered as an effective alternative to structure-based drug design [<ce:cross-ref id="crosref1160" refid="bib95">95</ce:cross-ref>]. The target binding mode of MEK1 and African Xenopus Aurora B/INCENP complex was studied by X-ray crystallography. The eutectic structure showed that BI-847325 was located in the ATP binding capsule in the hinge region of the two kinases, which played the role of ATP simulation [<ce:cross-ref id="crosref1165" refid="bib95">95</ce:cross-ref>]. The indolone scaffold itself is used as a hinge binding motif, and the linear and rigid alkynyl parts point to the interior of the kinase in the direction of the gate holder residue [<ce:cross-ref id="crosref1170" refid="bib95">95</ce:cross-ref>]. In vitro, BI-847325 showed growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC<ce:inf loc="post">50</ce:inf> ranging from 0.3 nM to 2 μM, and prevented colony formation in six BRAF-mutant melanoma cell lines. In the A375 model of BRAF<ce:sup loc="post">V600E</ce:sup> mutant melanoma cell line characterized by strong MAPK pathway activation, BI-847325 completely inhibited ERK phosphorylation at low concentration (<100 nM), and also inhibited the phosphorylation of direct substrate histone H3 of Aurora B in the same concentration range, effectively inhibited the phosphorylation of MEK and partially reduced the concentration of MEK protein [<ce:cross-ref id="crosref1175" refid="bib95">95</ce:cross-ref>]. It was found that equipotential effect was observed in BRAF mutant cells, while in KRAS mutant cells, MEK inhibition required higher concentration than Aurora kinase inhibition [<ce:cross-ref id="crosref1180" refid="bib95">95</ce:cross-ref>]. Biomarker analysis showed that this effect was mainly due to the inhibition of MEK in BRAF mutation model and Aurora kinase in KRAS mutation model, indicating that BI-847325 was effective in tumor models with BRAF and KRAS mutations in vitro and in vivo [<ce:cross-ref id="crosref1185" refid="bib95">95</ce:cross-ref>]. BI-847325 can effectively overcome the resistance of BRAF inhibitors by reducing the expression of MEK and Mcl-1 in vivo, and has a long-term inhibitory effect on BRAF mutant melanoma [<ce:cross-ref id="crosref1190" refid="bib100">100</ce:cross-ref>]. In mice bearing 1205Lu and 1205LuR xenografts, BI-847325 (75 mg/kg, p.o.) caused significant tumor suppression without significant alteration in the body weights [<ce:cross-ref id="crosref1195" refid="bib100">100</ce:cross-ref>].</ce:para>
                     <ce:para id="p0130" view="all">A phase I study using BI-847325 in patients with advanced solid tumors found that BI-847325 was safe, but because it was accompanied by adverse reactions (rash, visual impairment) in inhibiting MEK, it was considered that drug exposure was not enough to achieve dual MEK/Aurora inhibition, so the development of this drug was suspended [<ce:cross-ref id="crosref1200" refid="bib103">103</ce:cross-ref>]. However, the preclinical results of some studies have shown that the effective inhibition of MAPK pathway activity has been observed in all BRAF and NRAS mutant cancer cell lines, so in the future trials of BI-847325, the focus of the experiment can be shifted to patients who activate BRAF or NRAS mutation, so that they can give full play to their anti-tumor effect [<ce:cross-ref id="crosref1205" refid="bib103">103</ce:cross-ref>]. Studies have shown that drugs which inhibited the expression of MEK and Mcl-1, such as BI-847325, was very effective in eliminating disease and overcoming resistance to acquired BRAF inhibitors [<ce:cross-ref id="crosref1210" refid="bib100">100</ce:cross-ref>]. This kind of strategy is worthy of further clinical study in BRAF mutant melanoma [<ce:cross-ref id="crosref1215" refid="bib100">100</ce:cross-ref>]. The clinical trials of dual target inhibitors were shown in <ce:cross-ref id="opts0iupXsoDx" refid="tbl1">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">Aurora/VEGFR-2 dual inhibitor: 7-[1<ce:italic>H</ce:italic>-Indol-2-yl]-2,3-dihydro-isoindol-1-ones</ce:section-title>
                     <ce:para id="p0135" view="all">VEGF is one of the most important and effective angiogenesis factors, which is closely related to the growth and metastasis of a variety of tumors [<ce:cross-ref id="crosref1220" refid="bib104">104</ce:cross-ref>]. Overexpression in solid tumors has been proved to promote angiogenesis and tumor growth [<ce:cross-ref id="crosref1225" refid="bib35">35</ce:cross-ref>]. VEGFR-2 is a V (5) - type protein tyrosine kinase, located on the surface of endothelial cells, which is the main receptor of VEGF [<ce:cross-ref id="crosref1230" refid="bib105">105</ce:cross-ref>]. It consists of an extracellular component containing seven immunoglobulin-like domains, a transmembrane segment, a paramembrane segment, an intracellular protein tyrosine kinase domain containing 70–100 amino acid residues and a carboxyterminal tail [<ce:cross-ref id="crosref1235" refid="bib105">105</ce:cross-ref>]. It is the main medium for VEGF to stimulate endothelial cell migration, proliferation, survival and enhance vascular permeability [<ce:cross-ref id="crosref1240" refid="bib105">105</ce:cross-ref>]. VEGFR-2 has been found to be a key intermediate product of tumor angiogenesis and new vascular network formation required for tumor growth [<ce:cross-ref id="crosref1245" refid="bib106">106</ce:cross-ref>], with abnormally high expression levels in various tumor cells [<ce:cross-ref id="crosref1250" refid="bib107">107</ce:cross-ref>]. There is a lot of evidence that overactivation of VEGFR-2 is related to metastasis in most solid tumor patients [<ce:cross-ref id="crosref1255" refid="bib108">108</ce:cross-ref>]. Apatinib, a small molecule tyrosine kinase inhibitor, was found to strongly inhibit VEGFR-2 and significantly improve the median overall survival rate of gastric cancer (GC) patients who progressed to at least two chemotherapy regimens compared with placebo in phase III clinical trials [<ce:cross-ref id="crosref1260" refid="bib109">109</ce:cross-ref>]. Ramucirumab is a monoclonal antibody that binds to VEGFR-2 and is currently recommended for GC patients who have progressed after first-line treatment [<ce:cross-ref id="crosref1265" refid="bib110">110</ce:cross-ref>]. The inhibitory effect of small molecules on VEGFR-2 is an effective method to treat tumor, which has been widely concerned in recent years [<ce:cross-ref id="crosref1270" refid="bib35">35</ce:cross-ref>]. The dual inhibitor of VEGFR-2 and Aurora A is an attractive strategy, which may provide enhanced antitumor activity for many kinds of cancer [<ce:cross-ref id="crosref1275" refid="bib35">35</ce:cross-ref>].</ce:para>
                     <ce:para id="p0140" view="all">It has been observed that the VEGFR-2 kinase inhibitor SU11248 (Sunitinib) (<ce:bold>10</ce:bold>) and other effective kinase inhibitors can form pseudocycles through intramolecular hydrogen bonds [<ce:cross-ref id="crosref1280" refid="bib35">35</ce:cross-ref>]. It is believed that the intramolecular hydrogen bonds of these compounds kept them in a flat planar conformation, which will help to bind to the hinge region of the active site of protein kinases [<ce:cross-ref id="crosref1285" refid="bib35">35</ce:cross-ref>]. Based on this hypothesis, a new pharmacophore 1 (<ce:bold>10</ce:bold>) was proposed as a scaffold to inhibit protein kinase [<ce:cross-ref id="crosref1290" refid="bib35">35</ce:cross-ref>]. The molecular simulation confirmed that under the minimum energy conformation, there was a good hydrogen bond between pyrrolidine NH and isoindolone carbonyl oxygen molecules of pharmacophore 1, and showed good activity for VEGFR-2 (IC<ce:inf loc="post">50</ce:inf> = 1.10 μM) and Aurora kinase (IC<ce:inf loc="post">50</ce:inf> = 0.338 μM) [<ce:cross-ref id="crosref1295" refid="bib35">35</ce:cross-ref>]. After modeling the scaffold, a series of 7-[1<ce:italic>H</ce:italic>-indol-2-yl]-2,3-dihydro-isoindolin-1-ones (<ce:cross-ref id="crosref1699" refid="fig8">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>) were synthesized as inhibitors of VEGFR-2 [<ce:cross-ref id="crosref1300" refid="bib35">35</ce:cross-ref>]. It was found that they had double inhibitory effects on VEGFR-2 and Aurora A [<ce:cross-ref id="crosref1305" refid="bib35">35</ce:cross-ref>]. In this model, the isoindolone part of compound 12f (<ce:bold>11</ce:bold>) occupied the same space as the aminopyrimidine of ATP at the active site [<ce:cross-ref id="crosref1310" refid="bib35">35</ce:cross-ref>]. Glu-211’s main chain carbonyl and Ala213’s NH in the hinge region form a characteristic double hydrogen bond with 12f [<ce:cross-ref id="crosref1315" refid="bib35">35</ce:cross-ref>]. The study found that changing the pyrrole ring of pharmacophore 1 to an indole ring can increase the potency of VEGFR-2 by 10 times and the potency of Aurora A by 3 times [<ce:cross-ref id="crosref1320" refid="bib35">35</ce:cross-ref>]. Molecular simulations indicated that since the 5 position of the indole ring is solvent-exposed, substitution at this position should be allowed. Later, it was found that substitution with O(CH2)2morpholin-4-yl at the 5-position can obtain very effective VEGFR-2 and Aurora A inhibitors, so 12f was obtained [<ce:cross-ref id="crosref1325" refid="bib35">35</ce:cross-ref>].</ce:para>
                     <ce:para id="p0145" view="all">In order to evaluate the ability of these compounds to inhibit tumor in vivo, tumor xenotransplantation was carried out in nude mice, which showed in vivo activity and could effectively block the growth of cancer cells [<ce:cross-ref id="crosref1330" refid="bib35">35</ce:cross-ref>]. At present, there are not many studies on this series of compounds, but it provides a good method for the treatment of tumors and provides a way of thinking for the development and design of tumor drugs in the future.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">Aurora/ERK 2 dual inhibitor: (7-aryl-1, 5-naphthylpyridine-2-yl)urea</ce:section-title>
                     <ce:para id="p0150" view="all">Extracellular signal regulated kinase (ERK), a member of MAPK family, is a widely expressed hydrophilic non-receptor protein [<ce:cross-ref id="crosref1335" refid="bib111">111</ce:cross-ref>]. Its signaling pathway is the core of the signal network involved in regulating cell growth, development and division [<ce:cross-ref id="crosref1340" refid="bib111">111</ce:cross-ref>]. Human ERK1 and ERK2 are 84% identical in sequence and share many functions [<ce:cross-ref id="crosref1345" refid="bib111">111</ce:cross-ref>]. Signal transduction through ERK cascade is carried out by phosphorylation and activation of protein kinases at different levels. Raf kinases and MEK family have narrow substrate specificity. ERK1/2 catalyzes phosphorylation of hundreds of cytoplasmic and nuclear substrates, including regulatory molecules and transcription factors [<ce:cross-ref id="crosref1350" refid="bib112">112</ce:cross-ref>]. ERK phosphorylation usually involves a direct interaction between ERK and its substrate, and this interaction is usually mediated by two docking sites in ERK and two corresponding motifs in the substrate [<ce:cross-ref id="crosref1355" refid="bib113">113</ce:cross-ref>]. This type of docking promotes ERK phosphorylation and determines its specificity. Although in some cases, phosphorylation mediates changes in subcellular localization and docking interactions or can induce degradation and cause inhibition of certain substrates, phosphorylation of most substrates induces their activation [<ce:cross-ref id="crosref1360" refid="bib113">113</ce:cross-ref>]. Once activated, ERK1 and ERK2 participate in various cellular responses such as cell proliferation, survival, differentiation, motility, and angiogenesis [<ce:cross-ref id="crosref1365" refid="bib113">113</ce:cross-ref>]. ERK and its signaling pathways mediate and amplify signals during tumor invasion and metastasis. ERK over-activation can be found in many human cancers (such as oral cancer, melanoma, breast cancer, etc). Studies have shown that activation mutations in the upstream components of ERK1/2 cause more than half of cancers [<ce:cross-ref id="crosref1370" refid="bib114">114</ce:cross-ref>], but ERK1/2 is also activated in cancers where no mutations in the cascade components occur. The transfer of ERK1/2 to nucleus and other organelles was essential for the proliferation and metastasis of cancer cells [<ce:cross-ref id="crosref1375" refid="bib115">115</ce:cross-ref>]. Therefore, inhibition of ERK1/2 may be a potential therapeutic target for some diseases. The inhibition of ERK1/2 activity downregulated the protein expression and kinase activity of Aurora B, suggesting that Aurora B involved in the regulation of the MAPK pathway and the inhibition of Aurora B and ERK 2 may lead to better tumor inhibition.</ce:para>
                     <ce:para id="p0155" view="all">A new type of Aurora kinase inhibitor (7-aryl-1,5-naphthylpyridine-4-yl)urea has been developed for the treatment of malignant diseases based on the proliferation of pathological cells [<ce:cross-ref id="crosref1380" refid="bib116">116</ce:cross-ref>]. Among them, 1,5-naphthylpyridine derivatives have very good inhibitory activities on Aurora A and B [<ce:cross-ref id="crosref1385" refid="bib116">116</ce:cross-ref>]. In addition, the selectivity to seven cancer-related protein kinases was emphasized, but all compounds lacked anti-proliferative activity when tested on five tumor cell lines [<ce:cross-ref id="crosref1390" refid="bib116">116</ce:cross-ref>]. Therefore, a series of compounds were synthesized by changing the additional position of urea on 1,5-naphthidine ring from 4 to 2, and it was found that such compounds not only maintained inhibition of the Aurora B, but also showed good activity against ERK2, while none of the other tested kinases had an inhibitory effect [<ce:cross-ref id="crosref1395" refid="bib117">117</ce:cross-ref>]. In the low and submicromolar range, these molecules showed anti-proliferative activity in a variety of cancer cells [<ce:cross-ref id="crosref1400" refid="bib117">117</ce:cross-ref>]. Among them, the pyrazoline derivatives containing benzylurea at the position of 1,5-naphthylpyridine ring 2 (<ce:bold>12</ce:bold>) had the best inhibitory activity on ERK2 (IC<ce:inf loc="post">50</ce:inf> = 30 nM), and had selectivity on HCT116 cells (IC50 was 0.191 μM) [<ce:cross-ref id="crosref1405" refid="bib117">117</ce:cross-ref>]. Compared to other compounds, its potency was increased by about 10 times. Benzyl group might promote affinity through closer hydrophobic interaction with Tyr34 and Val37 residues in the P-cyclic order [<ce:cross-ref id="crosref1410" refid="bib117">117</ce:cross-ref>]. When the urea part of the compound containing benzyl group was found in the ATP pocket of human ERK2 toward the gatekeeper residue Gln103, the hydrogen bond with the ATP hinge residue Met106 was observed, and it was thought that the side-chain flexibility could engage this particular type of interaction even without additional hydrogen bonds (D = 3.51 between –NH and carbonyl) [<ce:cross-ref id="crosref1415" refid="bib117">117</ce:cross-ref>]. At present, the research on these compounds is still limited, and pharmacological experiments are still in progress to confirm their dual inhibitory effects [<ce:cross-ref id="crosref1420" refid="bib117">117</ce:cross-ref>]. However, additional ERK2 inhibition may lead us to design a very promising anti-tumor drug, and this SAR study provides a useful starting point for lead optimization [<ce:cross-ref id="crosref1425" refid="bib117">117</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0075">Aurora/PDK 1 dual inhibitor: SA16 (<ce:bold>13</ce:bold>)</ce:section-title>
                     <ce:para id="p0160" view="all">3-phosphoinositol-dependent protein kinase 1 (PDK1) is an ancient serine threonine kinase, belonging to the AGC kinase family [<ce:cross-ref id="crosref1430" refid="bib118">118</ce:cross-ref>], which is the main regulator of many downstream signal protein kinase cascades. It represents a convergence point of receptor tyrosine kinase and cytokine mediated pathways regulating cell survival and proliferation [<ce:cross-ref id="crosref1435" refid="bib119">119</ce:cross-ref>]. PDK1 plays a key role in cell migration regulation, participating in the invasion of tumor cells by regulating the invasive formation of tumor cells [<ce:cross-ref id="crosref1440" refid="bib120">120</ce:cross-ref>], the invasion of amoeba and collective cancer cells. Overexpression is associated with aggressive phenotypes and poor prognosis [<ce:cross-ref id="crosref1445" refid="bib118">118</ce:cross-ref>]. The pathological upregulation of PDK1 signal caused by tissue growth factor receptor activation and/or phosphatase and tensin homologs (PTEN) mutation significantly triggers downstream signals, such as PKB/AKT, which can promote tumor invasion, angiogenesis and progression [<ce:cross-ref id="crosref1450" refid="bib119">119</ce:cross-ref>]. PDK1 can phosphorylate and activate AKT. It has been studied that phenothiazine can specifically inhibit PDK1 kinase activity and AKT phosphorylation level, and can inhibit the growth and apoptosis of ovarian cancer cells induced by epidermal growth factor (EGF) [<ce:cross-ref id="crosref1455" refid="bib121">121</ce:cross-ref>]. It has been proved that the activation of PDK1/AKT pathway plays a key role in cell survival, proliferation and tumor development [<ce:cross-ref id="crosref1460" refid="bib121">121</ce:cross-ref>]. Therefore, PDK1/AKT pathway is considered as a key target of cancer intervention. Over expression of PDK1 and/or up regulation of PDK1 signal appear in many kinds of tumors [<ce:cross-ref id="crosref1465" refid="bib119">119</ce:cross-ref>]. The inhibition of small molecules on this protein kinase can effectively inhibit the proliferation of cancer cells, which is beneficial to the treatment [<ce:cross-ref id="crosref1470" refid="bib119">119</ce:cross-ref>]. However, specific targeted drugs, including anti PDK1 targeted drugs, have not shown significant clinical effect and are prone to drug resistance [<ce:cross-ref id="crosref1475" refid="bib122">122</ce:cross-ref>].</ce:para>
                     <ce:para id="p0165" view="all">At present, studies have shown that inhibition of PDK1 and Aurora A simultaneously plays a key role in cell survival/migration/differentiation, which may be an innovative strategy to overcome the resistance and recurrence of glioblastoma multiforme (GBM) [<ce:cross-ref id="crosref1480" refid="bib122">122</ce:cross-ref>]. GBM relapse and resistance to treatment are also related to the existence of GBM stem cells (GSCs) [<ce:cross-ref id="crosref1485" refid="bib122">122</ce:cross-ref>]. By blocking the key pathways related to stem cell maintenance, eradication of GSC library can effectively reduce its tumor potential [<ce:cross-ref id="crosref1490" refid="bib122">122</ce:cross-ref>]. Among these pathways, Aurora A has become an effective target. Blocking Aurora A pathway can inhibit the formation of GSC colonies and enhance the activity of some commonly used GBM chemotherapy drugs [<ce:cross-ref id="crosref1495" refid="bib122">122</ce:cross-ref>]. Some compounds classified as PDK1 inhibitors have also been proved to affect the activity of Aurora A [<ce:cross-ref id="crosref1500" refid="bib122">122</ce:cross-ref>]. The combination of MP7 (PDK1 inhibitor) (<ce:bold>14</ce:bold>) and Alisertib (Aurora A inhibitor) (<ce:bold>15</ce:bold>) can inhibit the proliferation of GBM and GSC cells, induce GBM apoptosis, but not toxic to normal cells [<ce:cross-ref id="crosref1505" refid="bib119">119</ce:cross-ref>,<ce:cross-ref id="crosref1510" refid="bib123">123</ce:cross-ref>], induce GSC differentiation and inhibit cell migration, which proved the effectiveness of the combination. PDK1/AKT and Aurora A pathway play a key role in the survival/migration of glioma cells and the self-renewal of glioma stem cell components. It is a new strategy to overcome the drug resistance and recurrence of glioma [<ce:cross-ref id="crosref1515" refid="bib122">122</ce:cross-ref>], and it can develop new potential drugs to affect the drug resistance of GBM to chemotherapy [<ce:cross-ref id="crosref1520" refid="bib124">124</ce:cross-ref>].</ce:para>
                     <ce:para id="p0170" view="all">In order to find and synthesis new scaffolds for the new PDK1 inhibitors, a new kind of oxide pyridyl compound was studied and designed [<ce:cross-ref id="crosref1525" refid="bib124">124</ce:cross-ref>]. Among these hybrids, SA16 was developed [<ce:cross-ref id="crosref1530" refid="bib122">122</ce:cross-ref>]. SA16 is considered to be a new ligand that can inhibit both PDK1 and Aurora A. It was originally designed as a PDK1 inhibitor to combine the known ATP binding site and two pharmacophore parts of DFG (outside the pocket of PDK1) through phenyl glycine linker [<ce:cross-ref id="crosref1535" refid="bib122">122</ce:cross-ref>]. The <ce:italic>Z</ce:italic>′-Lyte detection of SA16 on 56 kinases based on FRET showed that SA16 had significant inhibition on PDK1 (IC<ce:inf loc="post">50</ce:inf> = 416 nM) and Aurora A (IC<ce:inf loc="post">50</ce:inf> = 35 nM), which indicated that SA16 could be used as a prototype of dual PDK1/Aurora inhibitors, and could help to establish preclinical evidence of the mechanism of inhibition of both pathways at the same time [<ce:cross-ref id="crosref1540" refid="bib122">122</ce:cross-ref>]. This new pyridine oxide derivative had been shown to inhibit GBM cell proliferation, reduced tumor invasiveness and trigger apoptosis [<ce:cross-ref id="crosref1545" refid="bib122">122</ce:cross-ref>]. SA16 provided a promising multi-target therapy for GBM, increased the ability to consume GSC, and improved the prognosis of GBM [<ce:cross-ref id="crosref1550" refid="bib122">122</ce:cross-ref>]. According to the report, this was the first report about the combination targeting of PDK1 and Aurora A [<ce:cross-ref id="crosref1555" refid="bib122">122</ce:cross-ref>]. The drug is an attractive multi-target lead stent. Although there are not many types of research at present, it can be used to develop new methods for the treatment of GBM and GSCs [<ce:cross-ref id="crosref1560" refid="bib122">122</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0080">Perspective</ce:section-title>
                  <ce:para id="p0175" view="all">Cancer, as one of the diseases with extremely high mortality, affects the normal metabolism of the human body, destroys the normal tissue structure, and seriously affects the normal life of human beings. The destruction of the mitotic mechanism has been confirmed as an anti-cancer strategy. Studies have found that Aurora kinase is overexpressed and proliferated in a variety of human malignancies and is associated with high proliferation rates and poor prognosis [<ce:cross-ref id="crosref1565" refid="bib41">41</ce:cross-ref>]. Therefore, the use of Aurora kinase inhibitors to target tumors is becoming a research hotspot. At present, many small molecule Aurora kinase inhibitors have been discovered and tested in vivo and in vitro, some of which are undergoing phase II trials [<ce:cross-ref id="crosref1570" refid="bib41">41</ce:cross-ref>]. However, the inhibitory effect of aurora alone is not good, which may lead to drug resistance and side effects, so there is an urgent need for drugs with minimum cytotoxicity and can improve the prognosis and long-term quality of life of patients to treat cancer [<ce:cross-ref id="crosref1575" refid="bib43">43</ce:cross-ref>]. According to cancer therapeutics, single drug targeting multiple routes at the same time is better than single route in efficacy, tolerance and economy. Multi-target anti-tumor drugs have better efficacy than existing single-target anti-tumor drugs and can reduce the emergence of drug-induced resistance [<ce:cross-ref id="crosref1580" refid="bib42">42</ce:cross-ref>], which is very obvious in other kinds of anti-cancer drugs. Some studies have reported the benefits of combining Aurora kinase inhibitors with other anticancer drugs, such as cisplatin, temozolomide, taxane, vorinostat and nilotinib [<ce:cross-ref id="crosref1585" refid="bib65">65</ce:cross-ref>]. It is confirmed that blocking two or more signal pathways at the same time may reverse the drug resistance of targeted therapy, which provided a new idea for the treatment of cancer. Based on this, we reviewed the Aurora dual target inhibitors found in recent years and found that these inhibitors are indeed better than single-target inhibitors, which have the advantages of reducing drug resistance, reducing drug toxicity, and improving drug efficacy. Previous genetic and pharmacological studies indicated that targeting Aurora A and JAK2 together is a more effective approach than each kinase alone at inhibiting malignant transformation and warrant further advanced preclinical investigations of dual Aurora A/JAK2 inhibitors as potential anti-tumor agents [<ce:cross-ref id="crosref1590" refid="bib65">65</ce:cross-ref>]. Compound 54 exhibited good pharmacological and safety profiles in vitro and in vivo and an acceptable in vivo pharmacokinetic profile when administered intravenously. Structure-activity relationship studies demonstrated the significance of the 6-acylureido and 3-pyrrolemethylidene moieties attached to the indolin-2-one scaffold with respect to potent kinase inhibitory activity and cytotoxicity [<ce:cross-ref id="crosref1595" refid="bib77">77</ce:cross-ref>]. Although the safety of BI-847325 is good, it is accompanied by adverse reactions. Pre-clinical studies have shown that BI-847325 can effectively inhibit the activity of MAPK pathway in all BRAF and NRAS mutant cancer cell lines, so that it can fully exert anti-tumor efficacy [<ce:cross-ref id="crosref1600" refid="bib103">103</ce:cross-ref>]. These drugs represent an attractive multi-target lead scaffolds for the development of new potential treatments for cancers. However, most dual target inhibitors such as JNJ-7706621, AIJ-100, and SA16 have only proven their activity in preclinical studies. After entering clinical trials in the future, there may still be many problems such as toxicity and selectivity [<ce:cross-ref id="crosref1605" refid="bib43">43</ce:cross-ref>], and further drug development research may face obstacles. But the advantages of dual-target inhibitors can provide a good idea for the development of new drugs, and the design and research of targeted drugs need to be further optimized in the future to make the development of anticancer drugs more mature and reliable.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0085">Declaration of competing interest</ce:section-title>
               <ce:para id="p0180" view="all">The authors declare no competing interests.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0090">Acknowledgements</ce:section-title>
               <ce:para id="p0185" view="all">This work is funded by <ce:grant-sponsor id="gs5" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Key research development program of Science and Technology Department of Sichuan provincial</ce:grant-sponsor> (<ce:grant-number refid="gs5">2019YFS0514</ce:grant-number>). All authors declare no competing interests. The content of this article does not involve infringement of the property rights.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0095">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The hallmarks of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>70</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">R.A. Weinberg, The Hallmarks of Cancer, Cell, 100 (2000) 57-70.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hamhouyia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Girvan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>McGregor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.O.</ce:given-name>
                                 <ce:surname>Trent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Bates</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43221</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">X. Xu, F. Hamhouyia, S.D. Thomas, T.J. Burke, A.C. Girvan, W.G. McGregor, J.O. Trent, D.M. Miller, P.J. Bates, Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides, Journal of Biological Chemistry, 276 (2001) 43221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vogelstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lessons from hereditary colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>159</sb:first-page>
                              <sb:last-page>170</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">B. Vogelstein, Lessons from hereditary colorectal cancer, Cell, 87 (1996) 159-170.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mantovani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Allavena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Balkwill</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer-related inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>454</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>436</sb:first-page>
                              <sb:last-page>444</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature, 454 (2008) 436-444.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Vivanco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Sawyers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The phosphatidylinositol 3-Kinase–AKT pathway in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>489</sb:first-page>
                              <sb:last-page>501</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-Kinase-AKT pathway in human cancer, Nature Reviews Cancer, 2 (2002) 489-501.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kastan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.N.</ce:given-name>
                                 <ce:surname>Bartek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cell-cycle checkpoints and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>432</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>316</sb:first-page>
                              <sb:last-page>323</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">M. Kastan, J.J.N. Bartek, Cell-cycle checkpoints and cancer, Nature, 432 (2004) 316-323.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lengauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Kinzler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vogelstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genetic instabilities in human cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>396</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>643</sb:first-page>
                              <sb:last-page>649</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">C. Lengauer, K.W. Kinzler, B. Vogelstein, Genetic instabilities in human cancers, Nature, 396 (1998) 643-649.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.Y.</ce:given-name>
                                 <ce:surname>Jeng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpression and amplification of aurora-A in hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res. Off. J. Am. Assoc. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2065</sb:first-page>
                              <sb:last-page>2071</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Jeng, M. Y, Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma, Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 10 (2004) 2065-2071.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Tucker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Glaser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">J. Li, M.G. Anderson, L.A. Tucker, Y. Shen, K.B. Glaser, O.J. Shah, Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2, Cell Death & Differentiation, 16 (2009) 498.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Koh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitosis-targeted anti-cancer therapies: where they stand</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">K.S. Chan, C.G. Koh, H.Y. Li, Mitosis-targeted anti-cancer therapies: where they stand, Cell Death & Disease, 3 (2012).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Rieder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Maiato</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dev. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>637</sb:first-page>
                              <sb:last-page>651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">C.L. Rieder, H. Maiato, Stuck in Division or Passing through: What Happens When Cells Cannot Satisfy the Spindle Assembly Checkpoint, Developmental Cell, 7 (2004) 637-651.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hochegger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hegarat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Pereira-Leal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Open Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">H. Hochegger, N. Hegarat, J.B. Pereira-Leal, Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle, Open Biology, 3 (2013).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>Jackson</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Patrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted anti-mitotic therapies: can we improve on tubulin agents?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>107</sb:first-page>
                              <sb:last-page>117</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Jackson, Jr., D.M. Patrick, P. Huang, Targeted anti-mitotic therapies: can we improve on tubulin agents?, Nature Reviews Cancer, 7 (2007) 107-117.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Vader</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.A.</ce:given-name>
                                 <ce:surname>Lens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Aurora kinase family in cell division and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BBA Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1786</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>60</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">G. Vader, S.M.A. Lens, The Aurora kinase family in cell division and cancer, BBA - Reviews on Cancer, 1786 (2008) 60-72.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Carpinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Moll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors: identification and preclinical validation of their biomarkers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>69</sb:first-page>
                              <sb:last-page>80</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">P. Carpinelli, J. Moll, Aurora kinase inhibitors: identification and preclinical validation of their biomarkers, Expert Opinion on Therapeutic Targets, 12 (2008) 69-80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.C.M.V.D.</ce:given-name>
                                 <ce:surname>Weerdt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Medema</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polo-like kinases: a team in control of the division</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>853</sb:first-page>
                              <sb:last-page>864</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">B.C.M.V.D. Weerdt, R.H. Medema, Polo-like kinases: a team in control of the division, Cell Cycle, 5 (2006) 853-864.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tyagi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of cyclin dependent kinases: useful targets for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">P.S. Sharma, R. Sharma, R. Tyagi, Inhibitors of cyclin dependent kinases: useful targets for cancer treatment, Current Cancer Drug Targets, 8 (2008) -.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>O’Connell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.E.</ce:given-name>
                                 <ce:surname>Krien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Never say never. The NIMA-related protein kinases in mitotic control</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>221</sb:first-page>
                              <sb:last-page>228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">M.J. O’Connell, M.J.E. Krien, T. Hunter, Never say never. The NIMA-related protein kinases in mitotic control, Trends in Cell Biology, 13 (2003) 221-228.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nicholas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Stephen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora-kinase inhibitors as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>927</sb:first-page>
                              <sb:last-page>936</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">K. Nicholas, T. Stephen, Aurora-kinase inhibitors as anticancer agents, Nature Reviews Cancer, 4 (2004) 927-936.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cheung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Coumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors in preclinical and clinical testing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Invest. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>379</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">C. Cheung, M.H. Coumar, J. Chang, Aurora kinase inhibitors in preclinical and clinical testing, Expert Opinion on Investigational Drugs, 18 (2009) 379.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.K.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MLN-8237: a dual inhibitor of aurora A and B in soft tissue sarcomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12893</sb:first-page>
                              <sb:last-page>12903</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">J.S. Nair, G.K. Schwartz, MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas, Oncotarget, 7 (2016) 12893-12903.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dutertre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Descamps</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Prigent</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>On the role of aurora-A in centrosome function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>40</sb:issue-nr>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6175</sb:first-page>
                              <sb:last-page>6183</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">S. Dutertre, S. Descamps, C. Prigent, On the role of aurora-A in centrosome function, Oncogene, (2002).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tatsuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Toru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Makoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Shinichi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fuyuhiko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Noriyuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tomotoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hideyuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Akira</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2899</sb:first-page>
                              <sb:last-page>2905</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">H. Tatsuo, F. Toru, S. Makoto, E. Shinichi, M. Fuyuhiko, O. Noriyuki, M. Tomotoshi, S. Hideyuki, H. Akira, RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells, Cancer Research, 65 (2005) 2899-2905.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Walter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Seghezzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Korver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sheung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lees</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4906</sb:first-page>
                              <sb:last-page>4916</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">A.O. Walter, W. Seghezzi, W. Korver, J. Sheung, E. Lees, The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation, Oncogene, 19 (2000) 4906-4916.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Katayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tatsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>46219</sb:first-page>
                              <sb:last-page>46224</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">H. Katayama, H. Zhou, Q. Li, M. Tatsuka, S. Sen, Interaction and Feedback Regulation between STK15/BTAK/Aurora-A Kinase and Protein Phosphatase 1 through Mitotic Cell Division Cycle, Journal of Biological Chemistry, 276 (2001) 46219-46224.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carmena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Earnshaw</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cellular geography of aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>842</sb:first-page>
                              <sb:last-page>854</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">M. Carmena, W.C. Earnshaw, The cellular geography of aurora kinases, Nature Reviews Molecular Cell Biology, 4 (2003) 842-854.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5818</sb:first-page>
                              <sb:last-page>5827</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Choi, S. H, Phosphorylation of Histone H3 at Serine 10 Is Indispensable for Neoplastic Cell Transformation, Cancer Research, 65 (2005) 5818-5827.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Zimmerman</ce:given-name>
                                 <ce:surname>Wendy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Sparks</ce:given-name>
                                 <ce:surname>Cynthia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Doxsey</ce:given-name>
                                 <ce:surname>Stephen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amorphous no longer: the centrosome comes into focus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>122</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Wendy, Zimmerman, and, Cynthia, Sparks, and, Stephen, Doxsey, Amorphous no longer: the centrosome comes into focus, Current Opinion in Cell Biology, (1999).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.J.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias, Leukemia: official journal of the Leukemia Society of America</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia Res. Fund</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>671</sb:first-page>
                              <sb:last-page>678</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">A.S. Moore, J. Blagg, S. Linardopoulos, A.D.J. Pearson, Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias, Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, 24 (2010) 671-678.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Barr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gergely</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora-A: the maker and breaker of spindle poles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>120</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2987</sb:first-page>
                              <sb:last-page>2996</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">A.R. Barr, F. Gergely, Aurora-A: the maker and breaker of spindle poles, Journal of Cell Science, 120 (2007) 2987-2996.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Pollard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Michael</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and development of aurora kinase inhibitors as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2629</sb:first-page>
                              <sb:last-page>2651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">J.R. Pollard, M. Michael, Discovery and development of aurora kinase inhibitors as anticancer agents, Journal of Medicinal Chemistry, 52 (2009) 2629-2651.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Manfredi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ecsedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Meetze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Balani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Burenkova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Galvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hoar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Huck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>LeRoy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. United States Am.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4106</sb:first-page>
                              <sb:last-page>4111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">M.G. Manfredi, J.A. Ecsedy, K.A. Meetze, S.K. Balani, O. Burenkova, W. Chen, K.M. Galvin, K.M. Hoar, J.J. Huck, P.J. LeRoy, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase, Proceedings of the National Academy of Sciences of the United States of America, 104 (2007) 4106-4111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Vader</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The chromosomal passenger complex: guiding Aurora-B through mitosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JCB (J. Cell Biol.)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>173</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>833</sb:first-page>
                              <sb:last-page>837</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Vader, G, The chromosomal passenger complex: guiding Aurora-B through mitosis, Journal of Cell Biology, 173 (2006) 833-837.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tomonaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Nomura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chromosome instability and kinetochore dysfunction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Histol. Histopathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>191</sb:first-page>
                              <sb:last-page>197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">T. Tomonaga, F. Nomura, Chromosome instability and kinetochore dysfunction, Histology & Histopathology, 22 (2007) 191-197.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.V.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Emanuel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>O’Grady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rugg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Fuentes-Pesquera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Karnachi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Alexander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Middleton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>7-[1-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5130</sb:first-page>
                              <sb:last-page>5133</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">T.V. Hughes, S.L. Emanuel, H.R. O’Grady, P.J. Connolly, C. Rugg, A.R. Fuentes-Pesquera, P. Karnachi, R. Alexander, S.A. Middleton, 7-[1-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity, Bioorganic & Medicinal Chemistry Letters, 18 (2008) 5130-5133.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kawai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Suto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kitajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tatsuka</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7266</sb:first-page>
                              <sb:last-page>7272</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">A. Kanda, H. Kawai, S. Suto, S. Kitajima, S. Sato, T. Takata, M. Tatsuka, Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation, Oncogene, 24 (2005) 7266-7272.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Suto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Katayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.B.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tanino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Terada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tatsuka</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increased mitotic phosphorylation of histone H3 attributable to AIM-1/aurora-B overexpression contributes to chromosome number instability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5168</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">T. Ota, S. Suto, H. Katayama, Z.B. Han, F. Suzuki, M. Maeda, M. Tanino, Y. Terada, M. Tatsuka, Increased Mitotic Phosphorylation of Histone H3 Attributable to AIM-1/Aurora-B Overexpression Contributes to Chromosome Number Instability, Cancer Research, 62 (2002) 5168.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Tseng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Aie1 Dna Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>679</sb:first-page>
                              <sb:last-page>688</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">H.M. Hu, C.K. Chuang, M.J. Lee, T.C. Tseng, T.K. Tang, Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie1, Dna & Cell Biology, 19 (2000) 679-688.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yunting</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Roberta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Harsukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sevil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jin-Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mercedes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7392</sb:first-page>
                              <sb:last-page>7416</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">H.R. Lawrence, M.P. Martin, L. Yunting, P. Roberta, Y. Hua, G. Harsukh, O. Sevil, Z. Jin-Yi, K. Robert, R. Mercedes, Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors, Journal of Medicinal Chemistry, 55 (2012) 7392-7416.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Manfredi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ecsedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Meetze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Balani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Burenkova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Galvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hoar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Huck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>LeRoy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Sells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Stringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Stroud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Weatherhead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Wysong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Bolen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.F.</ce:given-name>
                                 <ce:surname>Claiborne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. United States Am.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4106</sb:first-page>
                              <sb:last-page>4111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">M.G. Manfredi, J.A. Ecsedy, K.A. Meetze, S.K. Balani, O. Burenkova, W. Chen, K.M. Galvin, K.M. Hoar, J.J. Huck, P.J. LeRoy, E.T. Ray, T.B. Sells, B. Stringer, S.G. Stroud, T.J. Vos, G.S. Weatherhead, D.R. Wysong, M. Zhang, J.B. Bolen, C.F. Claiborne, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase, Proceedings of the National Academy of Sciences of the United States of America, 104 (2007) 4106-4111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Woolery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mahadevan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Update on aurora kinase targeted therapeutics in oncology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>291</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">M.R. Green, J.E. Woolery, D. Mahadevan, Update on Aurora Kinase Targeted Therapeutics in Oncology, Expert Opinion on Drug Discovery, 6 (2011) 291.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Arai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tsuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Obuse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Maenaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Minami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ohba</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2417</sb:first-page>
                              <sb:last-page>2430</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">R. Arai, M. Tsuda, T. Watanabe, T. Ose, C. Obuse, K. Maenaka, A. Minami, Y. Ohba, Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo, European Journal of Cancer, 48 (2012) 2417-2430.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.L.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>178</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>468</sb:first-page>
                              <sb:last-page>483</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">T. Yuan, B.W. Qi, Z.L. Jiang, W.J. Dong, L. Zhong, L. Bai, R.S. Tong, J.Y. Yu, J.Y. Shi, Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade, European Journal of Medicinal Chemistry, 178 (2019) 468-483.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xiaohua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhiwei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.W.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yixue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Zong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of drug combinations: interaction and network perspectives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">J. Jia, Z. Feng, M. Xiaohua, C. Zhiwei, Z.W. Cao, L. Yixue, Y.X. Li, C.Y. Zong, Mechanisms of drug combinations: interaction and network perspectives, Nature Reviews Drug Discovery, 8 (2009) 111-128.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sanchez-Martinez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Lallena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Sanfeliciano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Dios</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015-2019)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">C. Sanchez-Martinez, M.J. Lallena, S.G. Sanfeliciano, A. de Dios, Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019), Bioorganic & Medicinal Chemistry Letters, 29 (2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Stuart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Rugg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Gruninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronghui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.P.</ce:given-name>
                                 <ce:surname>Angel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Wetter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Beth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Kruger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cheryl</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9038</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">E. Stuart, C.A. Rugg, R.H. Gruninger, L. Ronghui, F.P. Angel, P.J. Connolly, S.K. Wetter, H. Beth, W.W. Kruger, N. Cheryl, The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases, Cancer Research, 65 (2005) 9038.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The plant cell cycle: G1/S regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Euphytica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>223</sb:first-page>
                              <sb:last-page>236</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">W.H. Shen, The plant cell cycle: G1/S regulation, Euphytica, 118 (2001) 223-236.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Tyson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Attila</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Irreversible cell-cycle transitions are due to systems-level feedback</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>724</sb:first-page>
                              <sb:last-page>728</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">N. Bela, J.J. Tyson, G. Bela, C.N. Attila, Irreversible cell-cycle transitions are due to systems-level feedback, Nature Cell Biology, 9 (2007) 724-728.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Joan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>G1 cell-cycle control and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>432</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>298</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">M. Joan, G1 cell-cycle control and cancer, Nature, 432 (2004) 298.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Peter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronghui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Stuart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Steve</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3639</sb:first-page>
                              <sb:last-page>3641</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">S. Huang, J.C. Peter, L. Ronghui, E. Stuart, A.M. Steve, Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621, Bioorganic & Medicinal Chemistry Letters, 16 (2006) 3639-3641.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Enserink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Kolodner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An overview of Cdk1-controlled targets and processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Div.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">J.M. Enserink, R.D. Kolodner, An overview of Cdk1-controlled targets and processes, Cell Division, 5 (2010) 11.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marcos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mariano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cell cycle, CDKs and cancer: a changing paradigm</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>153</sb:first-page>
                              <sb:last-page>166</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">M. Marcos, B. Mariano, Cell cycle, CDKs and cancer: a changing paradigm, Nature Reviews Cancer, 9 (2009) 153-166.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronghui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shenlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Wetter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yanhua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.V.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Emanuel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Gruninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Fuentes-Pesquera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Rugg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4208</sb:first-page>
                              <sb:last-page>4211</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">L. Ronghui, P.J. Connolly, H. Shenlin, S.K. Wetter, L. Yanhua, W.V. Murray, S.L. Emanuel, R.H. Gruninger, A.R. Fuentes-Pesquera, C.A. Rugg, 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities, Journal of Medicinal Chemistry, 48 (2005) 4208-4211.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hirota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Naoko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Takashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tomotoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dongwei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Masayuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Katsuyoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hideyuki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora-A and an interacting activator, the LIM protein ajuba, are required for mitotic commitment in human cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>0-598</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0295">T. Hirota, K. Naoko, S. Takashi, M. Tomotoshi, Z. Dongwei, N. Masayuki, H. Katsuyoshi, S. Hideyuki, Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells, Cell, 114 (2003) 0-598.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Giet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Uzbekov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cubizolles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Le Guellec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Prigent</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Xenopus laevis aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XlEg5</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>274</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15005</sb:first-page>
                              <sb:last-page>15013</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">R. Giet, R. Uzbekov, F. Cubizolles, K. Le Guellec, C. Prigent, The Xenopus laevis Aurora-related Protein Kinase pEg2 Associates with and Phosphorylates the Kinesin-related Protein XlEg5, Journal of Biological Chemistry, 274 (1999) 15005-15013.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Maekawa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Yeast Cdk1 translocates to the plus end of cytoplasmic microtubules to regulate bud cortex interactions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>438</sb:first-page>
                              <sb:last-page>449</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Maekawa, H, Yeast Cdk1 translocates to the plus end of cytoplasmic microtubules to regulate bud cortex interactions, Embo Journal, 22 (2003) 438-449.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.M.</ce:given-name>
                                 <ce:surname>Noble</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical inhibitors of cyclin-dependent kinases : insights into design from X-ray crystallographic studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>269</sb:first-page>
                              <sb:last-page>278</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">M.E.M. Noble, J.A. Endicott, Chemical Inhibitors of Cyclin-Dependent Kinases : Insights into Design from X-Ray Crystallographic Studies, Pharmacology & Therapeutics, 82 (1999) 269-278.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yanhua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Steven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Peter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Ignatius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Stuart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.-P.</ce:given-name>
                                 <ce:surname>Angel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mary</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2221</sb:first-page>
                              <sb:last-page>2224</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">R. Lin, L. Yanhua, K.W. Steven, J.C. Peter, J.T. Ignatius, V.M. William, L.E. Stuart, H.G. Robert, R.F.-P. Angel, A. Mary, 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation, Bioorganic & Medicinal Chemistry Letters, 15 (2005) 2221-2224.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-c.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Maryanoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>McComsey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.E.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Conway</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Demarest</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Substituted pyrrolines as kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>United States Patent</sb:maintitle>
                              </sb:title>
                              <sb:date>2005</sb:date>
                           </sb:edited-book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">H.-c. Zhang, B.E. Maryanoff, D.F. McComsey, K. White, Y.E. Hong, L. Hecker, B.R. Conway, K. Demarest, SUBSTITUTED PYRROLINES AS KINASE INHIBITORS, in: United States Patent 2005.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.E.M.</ce:given-name>
                                 <ce:surname>Kitzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.A.</ce:given-name>
                                 <ce:surname>de Jonge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Verweij</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncol. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>99</sb:first-page>
                              <sb:last-page>110</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">J.J.E.M. Kitzen, M.J.A. de Jonge, J. Verweij, Aurora kinase inhibitors, Critical Reviews in Oncology/Hematology, 73 (2010) 99-110.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Matsuhashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ohno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nagano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kawai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saitou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Takigami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Okano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shimizu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>625</sb:first-page>
                              <sb:last-page>639</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">A. Matsuhashi, T. Ohno, M. Kimura, A. Hara, M. Saio, A. Nagano, G. Kawai, M. Saitou, I. Takigami, K. Yamada, Y. Okano, K. Shimizu, Growth Suppression and Mitotic Defect Induced by JNJ-7706621, an Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases, Current Cancer Drug Targets, 12 (2012) 625-639.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Danhier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ucakar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Magotteaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Brewster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Préat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20</sb:first-page>
                              <sb:last-page>28</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">F. Danhier, B. Ucakar, N. Magotteaux, M.E. Brewster, V. Preat, Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621, International Journal of Pharmaceutics, 392 (2010) 20-28.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Alexandra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Constantinescu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Semin. Cell Dev. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>385</sb:first-page>
                              <sb:last-page>393</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">V. William, D. Alexandra, S.N. Constantinescu, JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies, Seminars in Cell & Developmental Biology, 19 (2008) 385-393.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Haiying</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Dongqing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Golam</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differential biological activity of disease-associated JAK2 mutants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>585</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1007</sb:first-page>
                              <sb:last-page>1013</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">Z. Haiying, Y. Dongqing, M. Golam, Differential biological activity of disease-associated JAK2 mutants, Febs Letters, 585 (2011) 1007-1013.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Aslamuzzaman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Harsukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ronil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yunting</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Uwe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2947</sb:first-page>
                              <sb:last-page>2961</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Y. Hua, H.R. Lawrence, K. Aslamuzzaman, G. Harsukh, P. Ronil, L. Yunting, R. Uwe, S. Ernst, N.J. Lawrence, S.M. Sebti, Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation, Oncotarget, 5 (2014) 2947-2961.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pawel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barbara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Aleksandra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Anna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Paulina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pawel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Karolina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.P.</ce:given-name>
                                 <ce:surname>Monika</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tadeusz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Maciej</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>765</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>188</sb:first-page>
                              <sb:last-page>197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">G. Pawel, D. Barbara, S. Aleksandra, B. Anna, G. Paulina, T. Pawel, D. Karolina, L.P. Monika, P. Tadeusz, W. Maciej, Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors, European Journal of Pharmacology, 765 (2015) 188-197.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.C.</ce:given-name>
                                 <ce:surname>Alfonso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                              <sb:last-page>472</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">Q.C. Alfonso, The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications, Leukemia Research, 37 (2013) 465-472.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3: ITDoes matter in leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1738</sb:first-page>
                              <sb:last-page>1752</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">M. Levis, D. Small, FLT3: ITDoes matter in leukemia, Leukemia, 17 (2003) 1738-1752.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.U.</ce:given-name>
                                 <ce:surname>Kazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Lars</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>693</sb:first-page>
                              <sb:last-page>703</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">J.U. Kazi, R.N. Lars, Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling, Molecular Oncology, 7 (2013) 693-703.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Masson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rönnstrand</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1717</sb:first-page>
                              <sb:last-page>1726</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">K. Masson, L. Ronnstrand, Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3, Cellular Signalling, 21 (2009) 1717-1726.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>671</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">A.S. Moore, J. Blagg, S. Linardopoulos, A.D. Pearson, Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias, Leukemia, 24 (2010) 671.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of resistance to FLT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Resist. Updates</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8</sb:first-page>
                              <sb:last-page>16</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">S.H. Chu, D. Small, Mechanisms of resistance to FLT3 inhibitors, Drug Resistance Updates, 12 (2009) 8-16.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kubli-Garfias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Salazar-Salinas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Perez-Angel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Seminario</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The clinical development of FLT3 inhibitors in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Invest. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1377</sb:first-page>
                              <sb:last-page>1395</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">C. Kubli-Garfias, K. Salazar-Salinas, E.C. Perez-Angel, J.M. Seminario, The clinical development of FLT3 inhibitors in acute myeloid leukemia, Expert Opinion on Investigational Drugs, 20 (2011) 1377-1395.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shepherd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: implication for the choice of toxicology species</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Pharmaceut. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>139</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">F.L. Wood, S. Shepherd, A. Hayes, M. Liu, F.I. Raynaud, Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species, European Journal of Pharmaceutical Sciences, 139 (2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Löwenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Muus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ossenkoppele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rousselot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-Y.</ce:given-name>
                                 <ce:surname>Cahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ifrah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Martinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Amadori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Berman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sonneveld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jongen-Lavrencic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rigaudeau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Stockman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goudie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Faderl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jabbour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6030</sb:first-page>
                              <sb:last-page>6036</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">B. Lowenberg, P. Muus, G. Ossenkoppele, P. Rousselot, J.-Y. Cahn, N. Ifrah, G. Martinelli, S. Amadori, E. Berman, P. Sonneveld, M. Jongen-Lavrencic, S. Rigaudeau, P. Stockman, A. Goudie, S. Faderl, E. Jabbour, H. Kantarjian, Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia, Blood, 118 (2011) 6030-6036.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vassilios</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chongbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Butrus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Amir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Magda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Nathan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Sheldrake</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8721</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">B. Vassilios, C. Simon, S. Chongbo, A. Sian, A. Butrus, F. Amir, A.S. Moore, K. Magda, B. Nathan, P.W. Sheldrake, Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia, Journal of Medicinal Chemistry, 55 (2012) 8721.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Jagtap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B.</ce:given-name>
                                 <ce:surname>Kondekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Tseng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Chern</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>268</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">A.D. Jagtap, P.T. Chang, J.R. Liu, H.C. Wang, N.B. Kondekar, L.J. Shen, H.W. Tseng, G.S. Chen, J.W. Chern, Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia, European Journal of Medicinal Chemistry, 85 (2014) 268-288.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Tiziana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Serena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mariadomenica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Syed Khizer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Serena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Serena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Laura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Paola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Jonny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Michela</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>161</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>540</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">O. Tiziana, Z. Serena, D. Mariadomenica, H. Syed Khizer, L. Serena, L. Serena, C. Laura, P. Paola, D.G. Jonny, C. Michela, Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin, British Journal of Haematology, 161 (2013) 533-540.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <ce:other-ref id="sref79">
                        <ce:textref>M. Atkins, C.A. Jones, P. Kirkpatrick, Sunitinib maleate, Nat. Rev. Drug Discov., 5 279-280.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Large</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bouloc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kosmopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Matteucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wilsher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Martins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Reynisson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5213</sb:first-page>
                              <sb:last-page>5228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">V. Bavetsias, J. Large, C. Sun, N. Bouloc, M. Kosmopoulou, M. Matteucci, N. Wilsher, V. Martins, J. Reynisson, B. Atrash, Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate, Journal of Medicinal Chemistry, 53 (2010) 5213-5228.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perumal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.D.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of CCT129202, a novel Aurora kinase inhibitor and in vivo quantification of biological activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>3413S-3413S</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0425">F. Chan, C. Sun, M. Perumal, Q.D. Nguyen, S. Linardopoulos, Characterization of CCT129202, a novel Aurora kinase inhibitor and in vivo quantification of biological activity, Molecular Cancer Therapeutics, 6 (2007) 3413S-3413S.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faisal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>De Haven Brandon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Avery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Castro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>3554-3554</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0430">A. Moore, A. Faisal, V. Bavetsias, C. Sun, B. Atrash, M. Valenti, A. De Haven Brandon, S. Avery, D. Castro, F. Raynaud, P. Workman, A. Pearson, J. Blagg, S. Eccles, S. Linardopoulos, Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition, Cancer Research, 71 (2011) 3554-3554.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mizuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fenski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Halfter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Matsumura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hubert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>96</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3907</sb:first-page>
                              <sb:last-page>3914</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">M. Mizuki, R. Fenski, H. Halfter, I. Matsumura, S. Hubert, Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways, Blood, 96 (2001) 3907-3914.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.F.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faisal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D Gonzalez</ce:given-name>
                                 <ce:surname>de Castro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Haven Brandon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Avery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mirabella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Swansbury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.J.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">A.S.F. Moore, A; de Castro, D Gonzalez; Bavetsias, V; Sun, C; Atrash, B; Valenti, M; de Haven Brandon, A; Avery, S; Mair, D; Mirabella, F; Swansbury, J; Pearson, A D J; Workman, P; Blagg, J; Raynaud, F I; Eccles, S A; Linardopoulos, S, Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. %J Leukemia, Leukemia, 7 (2012).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jamieson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Moir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Rankovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wishart</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Medicinal chemistry of hERG Optimizations: highlights and hang-ups</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5029</sb:first-page>
                              <sb:last-page>5046</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">C. Jamieson, E.M. Moir, Z. Rankovic, G. Wishart, Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups, Journal of Medicinal Chemistry, 49 (2006) 5029-5046.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Summy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Gallick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src family kinases in tumor progression and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Metastasis Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>337</sb:first-page>
                              <sb:last-page>358</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">J.M. Summy, G.E. Gallick, Src family kinases in tumor progression and metastasis, Cancer & Metastasis Reviews, 22 (2003) 337-358.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Frame</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src in cancer: deregulation and consequences for cell behaviour</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BBA Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1602</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>114</sb:first-page>
                              <sb:last-page>130</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">M.C. Frame, Src in cancer: deregulation and consequences for cell behaviour, BBA - Reviews on Cancer, 1602 (2002) 114-130.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Brugge</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annual Review of Cell and Developmental Biology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>513</sb:first-page>
                              <sb:last-page>609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">S. Thomas, J.J.A.R.C.D.B. Brugge, Cellular functions regulated by Src family kinases, Annual Review of Cell and Developmental 13 (1997) 513-609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Collett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Erikson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase activity associated with the avian sarcoma virus src gene product</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. United States Am.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>1978</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2021</sb:first-page>
                              <sb:last-page>2024</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">M.S. Collett, R.L. Erikson, Protein kinase activity associated with the avian sarcoma virus src gene product, Proceedings of the National Academy of Sciences of the United States of America, 75 (1978) 2021-2024.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ishizawar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Src and cooperating partners in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>209</sb:first-page>
                              <sb:last-page>214</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">R. Ishizawar, S.J. Parsons, c-Src and cooperating partners in human cancer, Cancer Cell, 6 (2004) 209-214.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Maciej</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jianming</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Andreas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sofia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res. Off. J. Am. Assoc. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>924</sb:first-page>
                              <sb:last-page>935</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">L. Wei, K. Maciej, W. Jun, L. Jianming, H. Andreas, L. Sofia, Y. Yun, L. Frank, Y. Hua, W. Wei, Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment, Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 16 (2010) 924-935.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Frémin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Meloche</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>From basic research to clinical development of MEK1/2 inhibitors for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">C. Fremin, S. Meloche, From basic research to clinical development of MEK1/2 inhibitors for cancer therapy, Journal of Hematology & Oncology, 3 (2010) 8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cargnello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Roux</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Microbiol. Mol. Biol. Rev. Membr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>50</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">M. Cargnello, P.P. Roux, Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases, Microbiology & Molecular Biology Reviews Mmbr, 75 (2011) 50-83.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Raman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Cobb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differential regulation and properties of MAPKs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3100</sb:first-page>
                              <sb:last-page>3112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">M. Raman, W. Chen, M.H. Cobb, Differential regulation and properties of MAPKs, Oncogene, 26 (2007) 3100-3112.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Gurtler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Zahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rudolph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Baumgartinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Strauss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Haslinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Tontsch-Grunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.C.</ce:given-name>
                                 <ce:surname>Waizenegger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Solca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bader</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zoephel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Treu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Reiser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Garin-Chesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Boehmelt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kraut</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Quant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Adolf</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological profile of BI 847325, an orally bioavailable, ATP-competitive inhibitor of MEK and aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2388</sb:first-page>
                              <sb:last-page>2398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">P. Sini, U. Gurtler, S.K. Zahn, C. Baumann, D. Rudolph, R. Baumgartinger, E. Strauss, C. Haslinger, U. Tontsch-Grunt, I.C. Waizenegger, F. Solca, G. Bader, A. Zoephel, M. Treu, U. Reiser, P. Garin-Chesa, G. Boehmelt, N. Kraut, J. Quant, G.R. Adolf, Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases, Molecular Cancer Therapeutics, 15 (2016) 2388-2398.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Beers Gibson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karandikar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Berman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Cobb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Endocr. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>153</sb:first-page>
                              <sb:last-page>183</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">G. Pearson, F. Robinson, T. Beers Gibson, B.E. Xu, M. Karandikar, K. Berman, M.H. Cobb, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocrine reviews, 22 (2001) 153-183.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Caroline</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sandy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>MickaëL</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Karine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Maryline</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jean-Philippe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Philippe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Stéphane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Corine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>287</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29887</sb:first-page>
                              <sb:last-page>29898</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">B. Caroline, G. Sandy, O. MickaeL, B. Karine, A. Maryline, L. Jean-Philippe, B. Philippe, R. Stephane, B. Robert, B. Corine, Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells, Journal of Biological Chemistry, 287 (2012) 29887-29898.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Francesco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Giovanni Luca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Popov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Luca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Claudio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Maria Emilia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Silvia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Manuela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gemma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Corrado</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>285</sb:first-page>
                              <sb:last-page>294</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">M. Francesco, G. Giovanni Luca, V.M. Popov, S. Luca, F. Claudio, L.V. Maria Emilia, P. Silvia, C. Manuela, B. Gemma, F. Corrado, Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines, International Journal of Oncology, 44 (2014) 285-294.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Holt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Logié</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Odedra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Heier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Heaton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Alferez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wilkinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>858</sb:first-page>
                              <sb:last-page>866</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">S. Holt, A. Logie, R. Odedra, A. Heier, S. Heaton, D. Alferez, B. Davies, R. Wilkinson, P. Smith, The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models, British journal of cancer, 106 (2012) 858-866.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Phadke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Smalley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The novel ATP-competitive MEK/aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of Mcl-1 and MEK expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1354</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">M.S. Phadke, P. Sini, K.S. Smalley, The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression, Molecular Cancer Therapeutics, 14 (2015) 1354.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Ewings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hadfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulatory phosphorylation of Bim: sorting out the ERK from the JNK</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1008</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">R. Ley, K.E. Ewings, K. Hadfield, S.J. Cook, Regulatory phosphorylation of Bim: sorting out the ERK from the JNK, Cell Death & Differentiation, 12 (2005) 1008-1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Kiejda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gillespie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hersey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4934</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">Y.F. Wang, C.C. Jiang, K.A. Kiejda, S. Gillespie, X.D. Zhang, P. Hersey, Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1, Clinical Cancer Research, 13 (2007) 4934.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Schoffski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Aftimos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dumez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Deleporte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>De Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Costermans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Billiet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Meeus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Goeldner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Awada</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>99</sb:first-page>
                              <sb:last-page>108</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">P. Schoffski, P. Aftimos, H. Dumez, A. Deleporte, K. De Block, J. Costermans, M. Billiet, M.A. Meeus, C. Lee, D. Schnell, R.G. Goeldner, A. Awada, A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 77 (2016) 99-108.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Arjaans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Schröder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Oosting</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Dafni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.G.E.D.</ce:given-name>
                                 <ce:surname>Vries</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">M. Arjaans, C.P. Schroder, S.F. Oosting, U. Dafni, E.G.E.D. Vries, VEGF pathway targeting agents, vessel normalization and tumor drug uptake: From bench to bedside, Oncotarget, 7 (2016).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roskoski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Vascular endothelial growth factor (VEGF) signaling in tumor progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncol. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>179</sb:first-page>
                              <sb:last-page>213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0545">R. Roskoski, Vascular endothelial growth factor (VEGF) signaling in tumor progression, Critical Reviews in Oncology/Hematology, 62 (2007) 179-213.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shibuya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1097</sb:first-page>
                              <sb:last-page>1105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0550">Shibuya, M, Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies, Genes & Cancer, 2 (2001) 1097-1105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>183</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0555">W. Liu, Y. Lu, X. Chai, X. Liu, T. Zhu, X. Wu, Y. Fang, X. Liu, X. Zhang, Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases, Journal of Experimental & Clinical Cancer Research, 35 (2016) 183.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: synthesis, in vitro biological evaluation and molecular docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>126711</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0560">Y. Zhao, F. Liu, G. He, K. Li, C. Zhu, W. Yu, C. Zhang, M. Xie, J. Lin, J. Zhang, Y. Jin, Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking, Bioorganic & Medicinal Chemistry Letters, 29 (2019) 126711.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Randomized, double-Blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or Metastatic adenocarcinoma of the stomach or gastroesophageal junction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1448</sb:first-page>
                              <sb:last-page>1454</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>JCO.2015.2063.5995</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0565">J. Li, S. Qin, J. Xu, J. Xiong, C. Wu, Y. Bai, W. Liu, J. Tong, Y. Liu, R. Xu, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Journal of Clinical Oncology, (2016) JCO.2015.2063.5995.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tarazona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gambardella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huerta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Roselló</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Personalised treatment in gastric cancer: Myth or reality?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0570">N. Tarazona, V. Gambardella, M. Huerta, S. Rosello, A. Cervantes, Personalised Treatment in Gastric Cancer: Myth or Reality?, Current Oncology Reports, 18 (2016) 41.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Alison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Distinct functions for ERKs?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0575">C.L. Alison, Distinct functions for ERKs?, Journal of Biology, 5 (2006) 13.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ERK1/2 MAP kinases: structure, function, and regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>0-0</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0580">R. Robert, Jr., ERK1/2 MAP kinases: Structure, function, and regulation, Pharmacological Research, 66 (2012) 0-0.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Seger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Growth Factors</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0585">S. Yoon, R. Seger, The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions, Growth Factors, 24 (2006) 21-44.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Coppey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Grossman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ajuria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Jiménez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Paroush</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>hvartsman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MAPK substrate competition integrates patterning signals in the Drosophila embryo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>446</sb:first-page>
                              <sb:last-page>451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0590">Y. Kim, M. Coppey, R. Grossman, L. Ajuria, G. Jimenez, Z. Paroush, S.Y. hvartsman, MAPK Substrate Competition Integrates Patterning Signals in the Drosophila Embryo, Current Biology Cb, 20 (2010) 446-451.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Wortzel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Seger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The ERK cascade: distinct functions within various subcellular organelles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>209</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0595">I. Wortzel, R. Seger, The ERK Cascade: Distinct Functions within Various Subcellular Organelles, Genes & Cancer, 2 (2011) 195-209.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Julien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Maud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Marc Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tilmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pascal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 7〢ryl㏒ubstituted (1,5㎞aphthyridinl)ureas as Aurora Kinase Inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>217</sb:first-page>
                              <sb:last-page>232</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0600">D. Julien, A. Maud, B. Marc Le, S. Tilmann, M. Pascal, Discovery of 7〢ryl㏒ubstituted (1,5㎞aphthyridinl)ureas as Aurora Kinase Inhibitors, ChemMedChem, 9 (2014) 217-232.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Defaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Antoine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Logé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Le Borgne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Schuster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Seipelt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Aicher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Teifel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Günther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gerlach</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3748</sb:first-page>
                              <sb:last-page>3752</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0605">J. Defaux, M. Antoine, C. Loge, M. Le Borgne, T. Schuster, I. Seipelt, B. Aicher, M. Teifel, E. Gunther, M. Gerlach, Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells, Bioorganic & Medicinal Chemistry Letters, 24 (2014) 3748-3752.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Gagliardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>di Blasio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Primo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PDK1: a signaling hub for cell migration and tumor invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Rev. Canc</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1856</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>178</sb:first-page>
                              <sb:last-page>188</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0610">P.A. Gagliardi, L. di Blasio, L. Primo, PDK1: A signaling hub for cell migration and tumor invasion, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1856 (2015) 178-188.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peifer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Alessi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibitors of PDK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1810</sb:first-page>
                              <sb:last-page>1838</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0615">C. Peifer, D.R. Alessi, Small-Molecule Inhibitors of PDK1, Chemmedchem, 3 (2010) 1810-1838.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Gagliardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>di Blasio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Puliafito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Seano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sessa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chianale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bussolino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Primo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PDK1-mediated activation of MRCK? regulates directional cell migration and lamellipodia retraction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JCB (J. Cell Biol.)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>206</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>415</sb:first-page>
                              <sb:last-page>434</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0620">P.A. Gagliardi, L. di Blasio, A. Puliafito, G. Seano, R. Sessa, F. Chianale, T. Leung, F. Bussolino, L. Primo, PDK1-mediated activation of MRCK? regulates directional cell migration and lamellipodia retraction, Journal of Cell Biology, 206 (2014) 415-434.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.Y.</ce:given-name>
                                 <ce:surname>Yong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Cha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Ryu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Suh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential inhibition of PDK1/akt signaling by phenothiazines suppresses cancer cell proliferation and survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. N. Y. Acad. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                              <sb:last-page>403</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0625">J.H. Choi, R.Y. Yong, S.K. Lee, S.H. Kim, Y.H. Kim, J.Y. Cha, S.W. Oh, J.R. Ha, S.H. Ryu, P.G. Suh, Potential Inhibition of PDK1/Akt Signaling by Phenothiazines Suppresses Cancer Cell Proliferation and Survival, Annals of the New York Academy of Sciences, 1138 (2008) 393-403.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietrobono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Giacomelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chiellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Di Maio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.A.C.N.</ce:given-name>
                                 <ce:surname>Rapposelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of PDK1 and aurora kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>100</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0630">S. Daniele, S. Sestito, D. Pietrobono, C. Giacomelli, G. Chiellini, D. Di Maio, L. Marinelli, E. Novellino, C. Martini, S.J.A.C.N. Rapposelli, Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells, ACS Chemical Neuroscience, 8 (2017) 100-114.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>O’Donnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Salazar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Van Brocklyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Barnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Pearl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>deCarvalho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ecsedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mikkelsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>983</sb:first-page>
                              <sb:last-page>990</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0635">X. Hong, J.P. O’Donnell, C.R. Salazar, J.R. Van Brocklyn, K.D. Barnett, D.K. Pearl, A.C. deCarvalho, J.A. Ecsedy, S.L. Brown, T. Mikkelsen, The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation, Cancer Chemotherapy & Pharmacology, 73 (2014) 983-990.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nesi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Martelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Digiacomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Borghini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Calderone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lapucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Falasca</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>274</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0640">S. Sestito, G. Nesi, S. Daniele, A. Martelli, M. Digiacomo, A. Borghini, D. Pietra, V. Calderone, A. Lapucci, M. Falasca, Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme, European Journal of Medicinal Chemistry, 105 (2015) 274-288.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>